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ABSTRACT
A breast tumor with a histology report that lacks Estrogen Receptor, Progesterone
Receptor, and Human Epidermal Growth Receptor 2/neu is identified as a Triple
Negative Breast Cancer (TNBC). Women with TNBC compared to non-TNBC patients
have 50% increased risk for all-cause mortality and TNBC is reported to have poor
survival compared to other Breast Cancer sub-types. TNBC is an aggressive disease with
varied outcomes among race/ethnicities in the United States.
Chapter one is an introduction chapter that introduces the problem statement,
highlights the significance of the problem, provides the theoretical framework along with
its constructs and how it supports the proposed research.
Chapter two is a review of the available published literature on TNBC, its phenotype
and genotype, risk factors and ethnic differences among women of color. The literature
search covered a span of ten years’ articles published in the online journals such as
PubMed, CINAHL, Web of Science, and Medline and retrieved selected 85 journal
articles. The review also provides information on ethnic similarities and differences for
early detection, prevention, and treatment of TNBC.
Chapter three is a research article and the purpose of that chapter is to provide the
research questions and hypotheses related to specific aim one and two. Specific aim one
is to provide the age-adjusted and age-specific incidence rates on TNBC among major
races/ethnicities such as Non-Hispanic White, Non-Hispanic Black, Hispanic (all Races),
and Asian Pacific Islander. The study sample included all 18 registries of Surveillance
Epidemiology, and End Results. The chapter also provides TNBC phenotypic,
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demographic, and treatment characteristics among TNBC cases and ethnic differences
among them. For specific aim two, the sample includes five Asian sub-ethnicities,
Chinese, Asian Indian, Vietnamese, Filipina, and Korean women along with
Non-Hispanic White, Non-Hispanic Black and Hispanic women.
Chapter four discusses the research findings and discussion on TNBC compared to
non-TNBC cases, results from a binary regression model to predict TNBC risk among
women of color. Odds Ratio for significant variables to predict TNBC risk are presented.
Chapter five summarizes the dissertation by providing main findings and discussions.
The limitations of the research study are presented and recommendations from the study
are discussed. Finally, research implications developed from the study are listed.
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CHAPTER 1
INTRODUCTION
This dissertation focuses on the problem of triple negative breast cancer in women of
color. Chapter two will present a synthesis of research literature related to TNBC, risk
factors, ethnic differences for TNBC incidence rates, risk factors, with identification of
early detection methods, prevention, and treatment of TNBC recognized and used among
women of color. In Chapter three, research on TNBC incidence rates as well as
demographics, phenotypic and treatment characteristics of TNBC will be presented. The
Dissertation Research on identifying risk factors associated with TNBC and a discussion
of the prediction model to identify TNBC risk will be described in chapter four. Finally,
Chapter 5 summarizes the main findings of the dissertation research, with a discussion
about the limitations, recommendations and a discussion of how this research contributes
to existing knowledge of TNBC in women of color.
Statement of The Problem
A breast tumor with a histology report that lacks Estrogen Receptor, Progesterone
Receptor, and is Human Epidermal Growth Receptor 2/neu negative is identified as a
Triple Negative Breast Cancer (TNBC) (Goldhirsch et al., 2011). Patients designated as
TNBC compared to non-TNBC patients have a 50% increased risk for all-cause mortality.
TNBC has been significantly associated with non-Breast Cancer mortality such as
circulatory system diseases, other cancers or causes (Hazard Ratio/HR = 2.52, 95% C.I. =
1.71-3.70, p < 0.05) and Breast Cancer- specific mortality (HR = 3.04, 95% C.I. =
2.33-3.97, p < 0.05) (Lian et al., 2014).
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TNBC is reported to have poorer survival compared to other sub-types. TNBC cases
have been shown to be 200% significantly more likely to die of their disease compared to
other hormone/HER2 groups, after adjustment for age at diagnosis and stage at
presentation (p < 0.0001) (Matt, Mozayen, Gress, & Tirona, 2015). When TNBC women
were assessed for five years’ survival, there was a significant decrease for both local
(stage I and II) and regional disease (stage III) (p = 0.03 and 0.02 respectively), compared
to all other hormone/HER2 groups (Matt et al., 2015). A similar pattern has been
observed for TNBC stage IV disease as well (Matt et al.). The overall survival reported
by Lin et al., (2012) using National Comprehensive Cancer Network data was worse than
reported by Matt et al., (adjusted HR = 2.72, 95% C.I. =2.39-3.10). Other studies also
reported similar results to Matt et al.’s findings that survival for TNBC is worst compared
to other hormone sub-types (Parise & Caggiano, 2011; Bauer, Brown, Cress, Parise, &
Caggiano, 2007).
Among breast cancer cases, ethnic differences have been noted for TNBC survival
statistics. Hispanic women are four times more likely to die from TNBC compared to
HR+/HER2- women (Hazard Ratio = 4.05, 95% CI:3.35–4.90) (Banegas et al., 2014).
African American women also have been found to have higher mortality from TNBC
compared to Non-African American women (Christiansen, Chen, Gilmore, Pechar, &
Szabo, 2012) other breast cancer sub-types (Bauer et al., 2007). These women in addition
to poor survival have high breast cancer recurrence rate. Christiansen et al. (2012) reported
significantly higher 5-year recurrence rate for African Americans, 42.5% compared to 7%
among non-African Americans (p = 0.0005).
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Compared to Non-Hispanic White women, combined Asian/Pacific Islander women
(included Pacific Islander, Southeast Asian, Indian continent, Chinese, Japanese, Filipino,
Korean) had decreased mortality (HR = 0.84, 95% C.I. = 0.74 - 0.94) (Parise & Caggiano,
2016). The same study found significantly better survival rates for Asians (sub-ethnicities
combined) when compared to White women (p = 0.025) (Parise & Caggiano, 2016). Hence
TNBC is an aggressive disease with varied outcomes among races/ethnicities in the United
States. This dissertation research and other chapter information provide available literature
related to the problem statement and research study findings on assessment for differences
in TNBC incidence rates among Non-Hispanic White, Non-Hispanic Black, Hispanic (all
races), Chinese, Asian Indian, Vietnamese, Korean and Filipina women. Also, examination
of associations between phenotypic, demographic, and treatment variables of TNBC
among these eight groups of women, and how significant variables can be used to predict
TNBC risk among these women will be provided. The new information will help to
identify and focus on the plausible reasons for poor TNBC survival statistics among the
women of color.
Significance of The Problem
The National Cancer Database’ (Plasilova et al., 2016) described female invasive
breast cancers (n = 295,801) in U.S. women diagnosed between 2010-2011, and showed
TNBC ranked second in frequency after HR+ HER2- subtype. Similar findings on TNBC
ranking among other breast cancer subtypes was reported by (Llanos et al., 2015; Lund et
al., 2009). The most recent TNBC age-adjusted incidence rate for all TNBC cases
diagnosed in 2011 was 15.5 per 100,000 women for cases diagnosed in 2011 (Kohler et
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al., 2015). Published information on incidence rate for TNBC cases diagnosed is not
available since 2011.
The race/ethnic groups in Kohler et al.’s study was NH White, NH Black, Hispanics,
NH Asian/Pacific Islander. The TNBC age-adjusted rate was highest among
Non-Hispanic (NH) Black followed by NH White, Hispanics and NH Asian/Pacific
Islander (27.2, 14.4, 11.8, 10.3 per 100,000 person-years respectively) for the year 2011
(Kohler et al., 2015). However, rates were not available for Asian sub-groups. The Asian
female population is predicted to be approximately 7.7 million in 2020 (Projections of the
Asian alone population by age and sex for the United States: 2010 to 2050, 2014) and
based on TNBC frequency published by recent studies, approximately 11% of breast
cancer cases will be affected by TNBC (Plasilova et al., 2016). The predicted number is
8,342 to be diagnosed with TNBC who are Asian in the year 2020. Similarly, higher
numbers for NH Black, Hispanics and NH White can be predicted since their reported
TNBC frequencies are higher than Asian population (23.7%, 14.8%, 11.4%, respectively)
(Plasilova et al., 2016). These numbers signify the magnitude of TNBC.
Patients with TNBC compared to Non-TNBC patients experience increased number
of hospitalized days, increased number of emergency room visits and significantly (p <
0.0001) increased healthcare costs (Baser, Wei, Henk, Teitelbaum, & Xie, 2012). These
factors are an important reason for the high mortality risk faced by the TNBC women;
twice that of the Non-TNBC women (HR = 2.02, p < 0.0001) (Baser et al., 2012). The
predicted high TNBC frequency plus the increased healthcare costs portray the burden of
the disease for the public health system. In addition, the National Cancer Institute also
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affirmed that cancer burden has a significant impact on public health in the United States.
This institution also predicted that as the U.S. population continues to grow and age,
cancer’s impact on public health would continue to grow (Cancer and Public health,
2015).
Theoretical Framework
The Health Belief Model (HBM) was used as the theoretical framework for this
TNBC dissertation research (Hochbaum, 1958). Since TNBC is a known aggressive
cancer and believed to have an impact on public health, one of the ways for researchers to
address the issue is by using available large registries that have information about people
with cancer (Cancer and Public Health, 2015). This cancer specific information on
population groups can be used to detect trends that affect cancer patients and to identify
contribution of genetic factors, occupational, environmental, medical, and others to
cancer risk (Cancer and Public Health, 2015).
The HBM originally proposed that personal beliefs or perceptions about a disease
and strategies to decrease the disease occurrence could determine health behavior
(Hochbaum, 1958). HBM is a Mid-Range theory as it lies between everyday working
hypothesis and all-inclusive grand theories. Due to this property, the HBM has more
direct application to research and practice. Because of these qualities, the HBM has its
application for Healthcare Genetics research. It could be applied in a clinical setting for
assessing the perceptions, attitudes, and beliefs people have towards genetic testing.
Another use would be in conjunction with the cancer risk assessment models used in
research to assess the change in health behavior of individuals. Both quantitative and
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qualitative studies have the potential to incorporate the HBM across a wide range of
disease phenotypes.
Originally in the 1950s four theoretical constructs were used in the HBM model:
perceived seriousness, perceived susceptibility, perceived benefits, and perceived barriers.
Since then additional constructs have been added to the model; cues to action, motivating
factors, and self-efficacy.
Perceived Severity
The construct of perceived severity relates to an individual’s belief about the
seriousness or severity of a disease. A person in general may have beliefs about
difficulties a disease would create in one’s life and this along with medical information
and knowledge constitutes the perception of seriousness (Glanz, Lewis, & Rimer, 1997).
Perceived Susceptibility
The second construct identifies powerful perceptions as susceptibility or personal
risk and drives individuals to either adopt or abandon a behavior. Individuals can
perceive to have higher risk for a one specific disease and will engage in healthy behavior
and vice versa. The higher the risk perceived the increased likelihood of adopting healthy
behaviors (Glanz, Lewis, & Rimer, 1997).
Perceived Benefits
Perceived benefits are the construct is that guides determination if a person would
have an opinion that a new behavior has usefulness and decreases the risk for a disease.
When people adopt a new behavior, they believe that the healthy behavior will decrease
their chance of developing a disease and they strive to follow that behavior. This
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construct has an important role to play in adoption of secondary prevention behaviors
(Glanz, Lewis, & Rimer, 1997).
Perceived Barriers
This added construct is the individual’s own assessment of the obstacles that hinder
them from adopting a healthy behavior. Perceived barriers are very significant in
determining a behavior change (Janz & Becker, 1984; Glanz, Lewis, & Rimer, 1997). An
individual can perceive the seriousness of the disease, but the barriers would prevent one
from adopting a healthy behavior.
Cues to Action
Any event, person, or a thing that moves a person to change a behavior is a cue to
action. This construct could be an illness of a family member, media report, mass media
campaign, advice from others, reminder postcards from a health care provider, or a health
warning label on a product (Glanz, Lewis, & Rimer, 1997).
Self-Efficacy
Self-efficacy is the construct that describes a belief in one’s own ability to do
accomplish something in life. For example, without self-efficacy even if an individual
perceives the seriousness of a disease but does not believe that he/she can adopt a healthy
behavior, the new behavior will never be tried (Glanz, Lewis, & Rimer, 1997).
Health Belief Model Assumptions
The three assumptions that an individual will adopt a healthy behavior are: a) the
person believes that a negative health condition can be avoided; b) the person has a high
positive expectation that by engaging in a healthy behavior, one can avoid the negative
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health condition; and, c) the person believes that he/she can perform the healthy behavior
(Assumptions of HBM, 2017).
The HBM has potential links between theory, research, and practice. It meets the
criterion to be theory as it has a set of interrelated constructs, and it measures a systematic
view of a phenomenon (perceptions) for predicting a behavior. The approach of the HBM
to science is deductive in nature that it starts with a bigger picture and moves to the
details. The constructs are more abstract as they are perceptions. All constructs have their
conceptual and operational definitions. From its name, it is known that it is a model and a
model is a symbolic representation of a set of concepts, created to depict relationships, it
allows for investigation of the properties of the system and prediction of future outcomes.
The Health Belief Model guides the research in two ways. Firstly, a person can
perceive their susceptibility when cancer statistics are available and specific to them. For
example, an Asian American woman might know her susceptibility only when an
incidence rate is available on her population along with other related factors like age,
income level, insurance status, and others. Secondly, when an individual perceives the
seriousness of a disease, self-efficacy plays a role if there is belief in one’s own ability to
do something. For example, a woman with higher TNBC risk can opt for early detection
or prevention of the disease.
The HBM guides the research to focus on areas of “perceived severity” and
“perceived susceptibility.” Research variables such as TNBC tumor sizes, tumor stage,
tumor grade, lymph node invasion, and metastasis corresponds to the construct of
perceived severity of the disease and race/ethnicity, TNBC incidence rates, age at
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diagnosis, insurance status, median household income level while TNBC frequency
relates to the construct of perceived susceptibility of the disease. These two constructs of
the HBM guide our research purpose.
Review of Literature
TNBC frequency is varied among races/ethnicities. The NH Black women ranked
first in TNBC frequency followed by Hispanic, NH White, and NH Asian/Pacific
Islander groups (23.7%, 14.8%, 11.4%, 11.2% respectively) (Plasilova et al., 2016).
When individual ethnicities were compared, the study reported the following frequencies:
Black women (23.7%) followed by Asian Indian (15.6%), American Indian/Eskimo
(14.6%), Chinese (11.9%), Vietnamese (11.5%), Japanese (11.3%), and Filipino (8.9%)
rank in TNBC tumor frequency (p < 0.01 when compared to White women and
Non-TNBC tumors) (Plasilova et al., 2016). However, the incidences in Korean, Chinese,
Vietnamese, and Japanese women were non-significant when compared to Non-TNBC
and white women (Plasilova et al., 2016). Although it was observed that grouped Asian
ethnicities had the lowest frequency compared to NH Black, NH White and Hispanics,
when grouped individually the Asian ethnicities frequency rates were found to be higher.
Clinico-pathologic features of TNBC were also found to be associated with
race/ethnicity. Staging was an important variable and is based on primary Tumor (T),
regional lymph Nodes (N), and distant Metastases (M) See Appendix A for American
Joint Committee on Cancer staging manual 7th edition. Tao, Gomez, Keegan, Kurian, &
Clarke (2015) used California Cancer Registry data and showed that African American
women with Stage III TNBC had higher hazards of breast cancer death compared to
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Whites (n=103,498) after adjusting for tumor characteristics, first course of treatment,
neighborhood Socio Economic Status (SES) and insurance status (Tao et al., 2015).
When stratified by SES, Hispanic women in the lower quintile had a higher Hazard Ratio
for breast cancer-specific mortality than women from the highest quintile (Hazard
Ratio=1.76 versus 1.38 respectively) (Banegas et al., 2014). These statistics highlight the
greater TNBC risk for certain ethnic groups based on SES. More risk factors associated
with TNBC include age at diagnosis, insurance status, family history, reproductive
factors, BRCA mutation, and others.
Ethnic differences in prevention, early detection, and treatment have been published
in the literature. Healthcare provider referral and race/ethnicity were documented to be
significant factors in getting genetic testing done (Thompson et al., 2012; Cragun et al.,
2015; Ricks-Santi & McDonald, 2016). Factors associated with healthcare provider
referral for genetic testing and receiving genetic counseling were investigated in two
studies. Healthcare provider referral, household income greater than $35,000 in the year
prior to diagnosis, and insured with a private health insurance were strong predictors for
receiving a genetic counseling (Cragun et al., 2015).
Chapter two was a review manuscript and had the research question:
a) what is the most recently available TNBC incidence rate and frequency among
races/ethnicities?
b) what are the risk factors associated with TNBC and do they differ among
races/ethnicities?
c) What are the knowledge gaps in the TNBC phenotypic research?
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The research questions for the study that is reported in chapters three and four are
a)

Is there a difference in age-adjusted and age-specific incidence rates for TNBC

among races/ethnicities?
b) Are there differences in phenotypic, demographic, and treatment features of
TNBC tumors among races/ethnicities?
c) What are the variables that are associated with TNBC compared to non-TNBC
among the eight groups?
d) Will there be higher/lesser odds for any race/ethnic group to develop TNBC
compared to Non-Hispanic White women?
e) What are the predictors for TNBC compared to Non-TNBC among the eight ethnic
groups?
Surveillance Epidemiology and End Results (SEER) program by the National Cancer
Institute (NCI) is in operation since 1971 to provide information about cancer statistics on
the U.S. population. There are 18 SEER registries across the country and has data for all
cases diagnosed since 2000. SEER started with nine registries and since then has been
adding states and regions of different states to represent the demographics of the U.S.
population. The registries collect information about patient demographics, primary tumor
site, specific cancer markers such as the hormone receptor status, cancer stage at
diagnosis, first course of treatment, and patient survival (SEER Registries, n. d.). The
education and poverty levels of the SEER population is very much alike to the U.S.
population, but the percentage of foreign-born population is higher among the SEER
population (17.9% versus 12.8%) (Population Characteristics, n. d.)
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Data Collection by SEER
Cancer-related data are sent from sources such as hospital registries, pathology
laboratories, and physician offices to the SEER Program’s central cancer registry. The
information that is sent includes patient demographics, tumor identification, treatment
and outcome. Each patient and tumor is given a unique identifier and is a combination of
SEER participant number, patient ID number and record Number. Each registry gives a
unique eight-digit number for each patient that will be called the patient ID number. The
record number is the sequential number of the records that are received on a single patient
and is automatically generated by the computer. (SEER Research Data Record
Description, 2017).
SEER collects and codes information about neoplasm that include but not limited to
date of diagnosis, whether situ or malignant, the number of the tumor among the rest of
the primaries, primary site, side of the body where the tumor originated, and diagnostic
confirmation (via histology, non-microscopically, or unknown in case of death certificate
alone). SEER uses International Classification of Diseases for Oncology, 3rd edition to
specify histology of the tumor, behavior code that corresponds to the malignant potential
of the tumor (0 for benign and 3 for malignant), grade differentiation (grades I to IV),
stage of cancer, first course of therapy, treatment status to note if patient received
treatment or not, surgery at primary site or at other sites including lymph nodes, or the
reason if a surgery was not performed, information about other treatments are also
entered using SEER codes, and date of last follow-up or death. Annually SEER requires
all its registries to do a vital status check to indicate if the individual is alive or dead
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(SEER Research Data Record Description, 2017). SEER does not collect information
such as nativity status (foreign-born or U.S. born), hormone therapy information as a
treatment method, genetic mutation test results. Chemotherapy detail on patients is not
efficiently categorized; SEER has grouped “unknown” along with “no”. Hence caution
needs to be exercised to avoid interpretation biases.
Data quality is maintained by quality control activities and Data Management System
(SEER*DMS). The SEER*DMS supports all core cancer registry functions such as data
importing, editing, linkage, consolidation, and reporting. Since SEER has a centralized
system design, data quality and consistency is improved, efficiency increased as well as
increased sharing of knowledge and experience among registries (Quality Improvement,
n. d.).
Accessing SEER Data
To access SEER data, a Data-Use agreement form was signed (Appendix B). The
form for request is found at http://seer.cancer.gov/data/request.html. SEER registry data
was available free of charge. Permission to conduct the study was obtained from Clemson
University’s Institutional Review Board (Appendix C). The exempt review process was
undertaken as there were no patient identification details in SEER data. The required
forms were submitted and approved for the study. All the researchers were up-to-date on
Collaborative Institutional Training Initiative. Data collection and analysis was initiated
after obtaining IRB approval and gaining SEER access.
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Data Analysis
Special software download was necessary to access and analyze the data. SEER*Stat
was an available software to do statistical analysis and was directly downloaded from
internet. Software Package for Social Sciences (SPSS) version 24.0 was used to perform
statistical analysis for this study. A Binary logistic regression analysis was performed in
Chapter four when there is one categorical outcome variable and two or more predictor
variables which could be only continuous variables or both categorical and continuous
variables. Chi-square statistic was performed in Chapters three and four to analyze data
related to a research question that involved one categorical outcome and one categorical
predictor variable (Field, 2013). Statistical significance was declared when p value was
less than or equal to 0.05. SPSS statistical software version 24 was used for research
described in chapters three and four, whereas SEER*Stat software was used for a part of
the study described in chapter three alone.
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CHAPTER 2
TRIPLE NEGATIVE BREAST CANCER (TNBC) PHENOTYPIC AND
GENOTYPIC TRAITS AMONG WOMEN OF COLOR IN THE UNITED
STATES: A REVIEW
Introduction
Triple Negative Breast Cancer (TNBC) is a type of breast malignancy with a lack
of tumor expression for the Estrogen Receptor (ER-), Progesterone Receptor (PR-), and
Human Epidermal growth factor Receptor (HER-2-). See Table 2.1 for St. Gallen 2011
consensus for clinico-pathologic definition of intrinsic breast cancer sub-types
(Goldhirsch et al., 2011). TNBC is treated by breast-conserving surgery (lumpectomy),
mastectomy, radiotherapy, neoadjuvant treatment, and adjuvant systemic therapy (Wabha
& El-Hadaad, 2015). In the study by Lian et al (2014) TNBC patients compared to
Non-TNBC patients had 50% increased risk for all-cause mortality and even after
covariate adjustment TNBC was significantly (p < 0.05) associated with non-Breast
Cancer mortality due to circulatory system diseases, other cancers or causes (HR = 2.15)
and Breast Cancer-mortality (HR = 1.42). The purpose of the review is to, for the first
time, provide the available TNBC incidence and frequency data for different ethnicities,
describe the various phenotypes of TNBC in women of color (African-American women,
Hispanic, Asian sub-groups) and to compare/contrast the risk factors among them.
Second, to determine if there are a variety of mutations, especially for BRCA1 positive
and or triple negative phenotype in these groups. Finally, to determine what similarities
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or differences among races/ethnicties affect early detection, prevention and treatment for
women.
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Table 2.1
Surrogate Definitions for Intrinsic Breast Cancer subtypes
Intrinsic subtype
Luminal A

Clinico-pathologic definition
Luminal A; ER and /or PR+ HER2Ki-67 low (<14%)

Luminal B

Luminal B (HER2-); ER and /or PR+ HER2- Ki-67 high
Luminal B (HER2+); ER and /or PR+ HER2 overexpressed;
any Ki-67

Erb-B2

HER2 positive (non-luminal)

overexpression

ER and PR absent; HER2 overexpressed or amplified

Basal-like

Triple Negative (ductal),
ER and PR absent HER2 negative

Note. Definitions for terms. Adapted from “Strategies for subtypes--dealing with the
diversity of breast cancer: Highlights of the St. Gallen international expert consensus on
the primary therapy of early breast cancer 2011,” by A. Goldhirsch, W.C. Wood, A.S.
Coates, R.D. Gelber, B. Thurlimann, H.J. Senn, & Panel members, 2011, Annals of
Oncology: Official Journal of the European Society for Medical Oncology, 22(8), p.
1736-1747.
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Racial/ethnic differences for TNBC has been documented for cancer recurrences
(Kanaan et al. 2014), overall survival (Banegas et al., 2014; Bauer, Brown, Cress, Parise,
& Caggiano, 2007; Lin et al., 2012; Tao, Gomez, Keegan, Kurian, & Clarke, 2015), and
mortality (Lund et al., 2008; Matt, Mozayen, Gress, & Tirona, 2015; Parise & Caggiano,
2016). TNBC women were twice more likely to die from the disease compared to all
other Breast Cancer/BC subtypes (p < 0.0001) (Matt et al., 2015). Tao et al. (2015), used
California Cancer Registry data and showed that African American women with Stage III
TNBC had higher hazards of BC death compared to Whites (n=103,498) and this is after
adjusting for tumor characteristics, first course of treatment, neighborhood socio
economic status and insurance status. Also, worst breast cancer survival was found for
TNBC tumors diagnosed between Stages II and IV (Tao et al.).
Hispanic women with TNBC data recorded in California Cancer Registry were
reported to have poorer survival compared to women with HR+/HER2- tumors (Banegas
et al., 2014). In this study, when stratified by socio economic status, Hispanic women in
the lower quintile had HR for breast cancer-specific mortality higher than women from
the highest quintile (HR = 1.76 versus 1.38 respectively) (Banegas et al.). Parise and
Caggiano (2016), identified TNBC mortality for combined Asian/Pacific Islander (API)
was significantly lower compared to other Breast cancer sub-types (HR, 0.84; 95%CI,
0.74-0.94, p < 0.049). Individual ethnicity risks were not published as they were
non-significant (p > 0.05) (Parise & Caggiano, 2016).
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Methodology
A systematic synthesis of literature was completed on original research articles
published from January 2007 to February 2017 using the search engines PubMed,
CINAHL, and Web of Science Search terms included triple negative breast cancer,
Caucasians, African Americans, Hispanic Americans, Asian Indians, TNBC, BRCA
mutations. The search retrieved 900 articles that requested studies conducted in the
United States and published in English. Duplicates, reviews, commentaries, and studies
conducted in countries other than the United States were excluded. Next, reading through
the abstracts, studies that described tumor genetic profile, drug studies, animal model
studies, tumor expression studies, somatic BRCA mutations and studies on survival
outcomes were excluded. The final selection for review was 85 articles. All articles were
carefully reviewed for significant and non-significant data published on incidence,
frequency of TNBC, risk factors, phenotype and genotype of TNBC, and similarities
among early detection, prevention, as well as treatment. The tumor sub-types mentioned
in this review reference the exact terminology used by authors of the individual articles.
Similarly, terminology for race/ethnicity are used exactly as stated in the article, example:
Black, African American, or Non-Hispanic Black This dissertation followed the U.S.
Census Bureau definitions for Non-Hispanic White, Non-Hispanic Black. Non-Hispanic
white are white population who are not of Hispanic origin (U. S. Census Bureau, 1999).
Similarly, Non-Hispanic Black are Black population who are of not Hispanic origin.
Refer to Table 2.2 for review of terminology.
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Table 2.2
Review of Terminology
Terms

Definitions

Age-adjusted

A statistical method allowing comparisons of populations that

incidence rate

considers age-distribution differences between populations

Age-specific

The rate of incidence of a specific age group, calculated per

incidence rate

100,000 people

Odds Ratio

A measure of the odds of an event happening in one group
compared to the odds of the same event happening in another
group

Hazard Ratio

A measure of how often a event happens in one group compared
to how often it happens in another group, over time.

Tumor Stage

Stage provides a measure of disease progression, detailing the
degree to which the cancer has advanced.

Tumor Grade

A description of a tumor based on how abnormal the cancer
cells and tissue look under a microscope and how quickly the
cancer cells are likely to grow and spread.

Chemotherapy

Treatment that uses drugs to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing

Radiotherapy

The use of high-energy radiation from X-rays, gamma rays,
neutrons, protons, and other sources to kill cancer cells and
shrink tumors.

Hormone

Treatment that adds, blocks, or removes hormones.

therapy
Note. Review of Terminology (n. d.). National Cancer Institute Dictionary of Cancer
Terms. Retrieved from
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45110
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Incidence of Triple Negative Breast Cancer
The most recently reported age-adjusted incidence rate for TNBC, published by
Kohler et al. (2015), included data from the North American Association of Central
Cancer Registries (NAACCR) for patients with hormone (estrogen and progesterone)
receptors and HER2 receptor information. The overall age-adjusted incidence rate for
TNBC was 15.5 per 100,000 person-years. When categorized by race/ethnicties the rate
was highest among Non-Hispanic (NH) Black followed by NH White, Hispanics and NH
Asian/Pacific Islander (27.2, 14.4, 11.8, 10.3 per 100,000 person-years respectively) for
the year 2011 (Kohler et al., 2015). The National Cancer Database’ (Plasilova et al., 2016)
described female invasive breast cancers (n=295,801) diagnosed between 2010-2011, and
showed TNBC ranked second in frequency after HR+ HER2- subtype. Similar to results
by Llanos et al. (2015) for New Jersey women diagnosed from 2006-2012, Lund et al.
(2009) found TNBC was ranked second in frequency after the HR+/HER2- breast cancer
subtype (98.9 versus 27.8 per 100,000) (Lund et al.,2009) in women diagnosed between
the years 2003 and 2004 in the Atlanta Surveillance Epidemiology End Results (SEER)
and Georgia Comprehensive Cancer registries. However, these results were from
predominantly White and Black populations with only 3.3% from other race/ethnicities
(Lund et al., 2009).
The NH Black group of women ranked first in TNBC frequency followed by
Hispanic, NH White, and NH Asian/Pacific Islander groups (23.7%, 14.8%, 11.4%,
11.2%, respectively) (Plasilova et al., 2016). Comparing NH Black and NH white women,
the NH Black women had an age-adjusted rate of 36.3, almost twice the rate compared to
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the age-adjusted rate of 19.4 in NH White women, (Lund et al., 2009). Similar results
published by Phipps et al. (2011) found TNBC in NH White women as 2.44 cancers per
10,000 person-years compared to 4.57 cancers per 10,000 person-years among African
American women. This study used cases diagnosed between 1993-1998 and was
restricted to women aged 50 to 79 years (Phipps et al., 2011).
Incidence differences between TNBC and Non-TNBC tumors among ethnic
minorities compared to White women have been reported by a variety of researchers.
See Table 2.3 Next to Black women (23.7%), Asian Indian (15.6%), American
Indian/Eskimo (14.6%), Chinese (11.9%), Vietnamese (11.5%), Japanese (11.3%), and
Filipino (8.9%) rank highest in TNBC tumor frequency (Plasilova et al., 2016). However,
the incidences in Korean, Chinese, Vietnamese, and Japanese women were
non-significant (Plasilova et al.).
Most recently Plasilova et al. reported age-specific TNBC frequency in the age group
< 30 years, was highest with a frequency of 23.3% with the remaining groups with 10
year ranges from 30 years to >70 years which revealed a declining trend for TNBC from
21.1% to 10%. Finally, HR+ HER2- had an inverse trend across the age groups. TNBC
age-specific incidence rate using data from SEER registries showed NH Black women to
be highest in TNBC frequency across all age-groups with the peak among those 65 to 69
years compared to women of other races (Howlader et al. 2014). The TNBC age-specific
incidence rate for NH Blacks for the age-group 65 to 69 years was 69.5 compared to 36.8
among NH Whites, 28.8 among Hispanics and 23.6 among NH Asian Pacific Islander of
the same age, all rates per 100,000 (Howlader et al., 2014). Similar results published by
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Amirikia et al. (2011) used information from the California Cancer Registry (n=375,761).
Clarke et al. (2012) found that Black women have an elevated TNBC age specific
incidence rate compared to White, Hispanics, and Asian (study sample, n=9,737 TNBC
cases) and reported the TNBC incidence rate ratios by comparing relative risk of an
ethnic group to a specified reference group (Clarke et al.). For Black versus White
women, aged 35 years and above, the TNBC Incidence rate ratio was significantly greater
than 1.0 (p < 0.05) (Clarke et al.). For Asian versus White women, the TNBC incidence
rate ratio for women more than 35 years of age, was found to be less than 1.0; for
Hispanic vs, white TNBC women more than 55 years, incidence rate ratio less than 1.0 (p
< 0.05) (Clarke et al.).
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Table 2.3
Journal Articles Published on TNBC Incidence
Authors/Year
Plasilova et al., 2016

Data Source, Years

Sample Population

National Cancer Database

NH White, NH Black, NH

(NCDB), 2010-2011

API, Hispanic, Other
(n=295,801)

Llanos et al., 2015

Women in New Jersey

African American, White

(Breast Cancer Treatment

(n=629)

Disparity Study), 2006-12
Kohler et al., 2015

Howlader et al., 2014

Clarke et al., 2012

Phipps et al., 2011

North American

Non-Hispanic White (NH),

Association of Central

NH Black, Hispanic, NH

Cancer Registries

Asian/Pacific Islander

(NAACCR), 2011

(API) (n*)

17 Registries from SEER,

NH White, NH Black, NH

2010

API, Hispanic (n=57,843)

California Cancer Registry

White, Black, Hispanic,

(CCR) 2006-2009

Asian (n=91,908)

Women’s Health

NH White, Hispanic or

Initiative, 1993-1998

Latina, African American,
Other (n=155,723)

Amirikia et al., 2011

Lund et al., 2009

California Cancer

NH White, NH Black,

Registry, 1988-2006

Hispanic (n=375,761)

Metropolitan Atlanta

White and Black women

SEER Registry (MASR)

(n=1,842)

and Georgia
Comprehensive Cancer
Registry (GCCR), 2003-04
Note. n*- Population used in calculation for the year 2011 was not provided.
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Phenotype of Triple Negative Breast Cancer
Tumor Histology
Seven studies report that TNBC’s histology is often presented as ductal carcinoma
(Plasilova et al., 2016; Llanos et al., 2015; Orucevic et al., 2015; Kanaan et al., 2014;
Swede et al., 2011; Tawfik et al., 2010; Telli et al., 2011). These tumors are significantly
less likely to be lobular or mixed compared to the ductal type (p = 0.001) (Rummel,
Varner, Shriver, & Ellsworth, 2013; Swede et al.) and a retrospective study with 700
cases reporting a significant finding of only 2.4% lobular versus 89% ductal cancers (p =
0.003) (Tawfik et al.), and 94% ductal carcinoma (Rummel et al., 2013). Llanos et al.
(2015), reported 91.2% to be invasive ductal and significantly different from other
subtypes that ranged in frequency from 80.2% to 85.7% (p = 0.0006). Swede et al. (2011)
used the Connecticut Tumor Registry of White and Black women diagnosed 2000-2003,
to report that TNBC was found to be 3.37 times more likely to be medullary type
(non-significant, p = 0.06) compared to all other BC-subtypes. There are also other
histologic sub-types reported for TNBC from adenoid cystic to tubular carcinoma (78.2%
to 0.3%), and for few of those types there was no significant difference with other BC
subtypes (Plasilova et al.).
Tumor Stage
Studies report TNBC to be staged by the American Joint Committee on Cancer
(AJCC) at stage II and above; a finding reported by eight studies (Parise & Caggiano,
2017; Bauer et al., 2007; Brown, Tsodikov, Bauer, Parise, & Caggiano, 2008; Lin et al.,
2012; Llanos et al., 2015; Rizzo et al., 2009; Rummel et al., 2013; Lund et al., 2010).
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There was a high frequency of stages II, III, and IV noted among TNBC compared to
Luminal type A cancers (65.8% versus 46.8% respectively); 17.7% of TNBC cases were
stages 3 and above versus 11.2% Luminal type A (Parise & Caggiano, 2017), 53.8% of
the TNBC cases were stage II and above, significantly different from 38.8% among
Luminal A cancers (p = 0.0087) (Llanos et al., 2015) and 60% of TNBC cases are greater
than stage II at presentation in a Clinical Breast Care Project (n=190 TNBC cases)
(Rummel et al., 2013). A retrospective chart review of women diagnosed from 2000-2006
with Stage III breast cancer in a single inner-city cancer center revealed TNBC tumors in
high proportions (29%) (Rizzo et al., 2009). TNBC tumors had significantly (p = .049)
higher frequencies in regional and distant tumors compared to patients with local disease
(25.1% and 27.8% versus 18.3%, respectively) (Swede et al., 2011). Zaky et al. (2011)
reported non-significant (p = 0.728) differences between TNBC and non-TNBC tumors
for AJCC stages I-III and non-significant (p > 0.05) higher odds were reported for TNBC
tumors of stages III and IV compared to lower stages (Lund et al., 2010; Lund et al., 2008;
Trivers et al., 2009; Telli et al., 2011).
Tumor Size
Eight studies report findings of TNBC tumor size >2 cms (Plasilova et al., 2016;
Parise & Caggiano, 2017; Llanos et al., 2015; Santebennur et al., 2008; Sineshaw et al.,
2014; Lund et al., 2010; Kanaan et al., 2014; Banegas et al., 2014). Findings from Parise
and Caggiano (2017) showed that 55.6% of TNBC tumors were >2 cms at presentation
versus 34.5% among Luminal A subtype. Like findings noted by Lund et al., 2009,
Sineshaw et al. (2014) found that TNBC significantly (p < 0.0001) ranked second in
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frequency to HR+ HER2- for tumors >5 cms in diameter. Mean tumor size reported by
Plasilova et al. (2016) for TNBC was significantly (p < 0.001) higher than HR+/HER2(2.78 cms versus 2.04 cms, respectively). Only 16.5% of the TNBC cases were <1 cm
compared to 40.5% in Luminal A cancers (Llanos et al.). Compared to estrogen
Receptor+ tumors, TNBC tumors are significantly (p < 0.05) >2 cms in mean diameter at
presentation (Kanaan et al., 2014).
Three studies (Brown et al., 2008; Bauer et al., 2007; Tawfik et al., 2014) reported
median size as 2 cms or above for TNBC, significantly (p < 0.001), different from 1.7
cms in other BC subtypes. Two studies (Orucevic et al., 2015; Zaky et al., 2011) reported
no statistically significant differences (p > 0.05, p = 0.06 respectively). The
non-significant findings could be due to the differences in sampling, women from one
group of race/ethnic origin (Orucevic et al., 2015) and a relatively small sample size from
a geographic location (Zaky et al., 2011).
Tumor Grade
Tumor grade is the description of how abnormal the tumor cells appear under a
microscope and they indicate how quickly a tumor can grow and spread. It is classified as
Grade I (well differentiated), Grade II (Moderately differentiated), Grade III (Poorly
differentiated), and Grade IV (Undifferentiated). It is used by doctors to determine a
patient’s prognosis and to develop a treatment plan (AJCC Tumor Grade, 2010). TNBC
frequently are high grade tumors with a majority classified as grade II and above. Fifteen
studies reported a significant association (p < 0.05) of high grade tumors with TNBC
(Plasilova et al., 2016; Parise & Caggiano, 2017; Sineshaw et al., 2014; Llanos et al.,
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2015; Tawfik et al., 2014 Orucevic et al., 2015; Morris et al., 2007; Lund et al., 2009
Lund et al., 2008; Banegas et al., 2014; Zaky et al., 2011; Rummel et al., 2013; Brown et
al., 2008; Bauer et al., 2007; Kanaan et al., 2014) and that patients with TNBC tumors
consistently presented with higher grade tumors compared to other breast sub-types or
Luminal type A cancer depending on the study methodology. The TNBC frequency for
grade III and higher tumors ranged from 64.7% to 100% in the above referenced research
articles.
Odds Ratio for a TNBC to be higher grade ranged from 9.7 times compared to BC
sub-types (Llanos et al., 2015) to 17 times compared to Luminal A cancer (Sineshaw et
al., 2014). A few other studies reported TNBC to have higher odds for higher grade
tumors (Kanaan et al., 2014; Orucevic et al., 2015; Telli et al., 2011). Howlader et al.
(2014) found TNBC patients were 20 times more likely to present with high grade tumors
after controlling for race, age and stage of disease. Irrespective of TNM staging, TNBC
tumors presented with high histologic grade and high Nottingham score compared to
Non-Triple negative phenotype (Orucevic et al., 2015). Also, non-significant higher odds
of 29.5 (95% CI 26.4-33.0) were reported for grade III tumors (versus grade I) associated
with TNBC (Telli et al., 2011).
Lymph Node Invasion
Four studies reported findings for TNBC related to lymph node invasion (Plasilova et
al., 2016; Banegas et al., 2014; Llanos et al., 2015; Khan et al., 2009). Plasilova et al.
found a significant (p < 0.001) association between lymph node invasion (positive) and
TNBC versus HR+HER2- tumors, reported as 25% of TNBC cases versus 19% among
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HR+ HER2 -. Llanos et al. (2015) reported 19.8% of TNBC cases versus 18.1% of
Luminal A cancers positive for lymphovascular invasion. Among Hispanic women with
breast cancer, positive lymph node invasion was reported with significant (p < 0.05) odds
ratio of 0.54 for TNBC compared to HR+/HER2- (Banegas et al., 2014). Similarly, Khan
et al. (2009) reported a frequency of 51.4% positive for lymphnode invasion in a
predominantly (~95%) Hispanic sample.
TNBC tumors can also present with clinically metastatic disease (Plasilova et al.,
2016). Compared to Non-TNBC cases, TNBC cases showed significance (p = 0.010) for
a high frequency of both local and distant metastasis (Zaky et al., 2011). Non-statistically
significant differences were noted between African American and Caucasian women for
local and distant metastatic disease (p = 0.450) (Zaky et al., 2011). Though not
statistically different in this study, African American women had double the rate for local
metastasis and triple the rate for distant metastasis compared to Caucasian women (p =
0.450) (Zaky et al.).
Are there differences in TNBC Phenotype Among Women of Color?
Original research articles were reviewed to synthesize information published on
differences in TNBC phenotypes among women of color. The race/ethnic origins
included in the studies reviewed were NH White, NH Black, Hispanic and Asians.
African American and Caucasian women
Significant differences between African American and Caucasian women with
TNBC were reported by six studies (Chen &Li, 2015; Tao, Gomez, Keegan, Kurian, &
Clarke, 2015; Chu, Henderson, Ampil, & Li, 2012; Swede et al., 2011; Tawfik et al.,
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2014; Sullivan et al., 2014). Chen and Li (2015) reported African American and
American Indian/Alaska Native women often present with stages II, III and IV compared
to Stage I in NH White, a significant finding (p < 0.05). However, Filipinos and Pacific
Islanders also often presented as Stages III/IV versus Stage I but a non-significant finding
(p > 0.05) (Chen &Li). Chinese and Japanese often presented more often with Stage I
compared to Stages II and above, also a non-significant finding (p > 0.05) (Chen &Li).
Chen and Li also reported larger tumors in African American women compared to other
ethnic groups.
For TNBC ductal carcinomas, Black women had higher frequency compared to
White women (34.8% versus 11.7%, p < 0.001) (Swede et al., 2011). Also, significant
differences were found in the average size of a TNBC tumor between African
American/AA and Caucasian American (3.23 cms versus 2.02 cms respectively, p <
0.001) (Sullivan et al., 2014). Significant differences for grade (Chu et al., 2012), and for
Lymphovascular invasion (44% in AA women versus 33% in Caucasian women
respectively, p = 0.039) (Tawfik et al., 2014) has been reported.
Non-significant (p > 0.05) ethnic differences were reported for multiple variables in
five studies (Sullivan et al., 2014; Tawfik et al., 2014; Chu et al., 2012; Pacheco, Gao,
Bumb, Ellis, & Ma, 2013; Sturtz, Melley, Mamula, Shriver, & Ellsworth, 2014). No
significant differences were reported for tumor stage (Chu et al., 2012; Pacheco et al.,
2013), tumor size distribution (Chu et al., 2012; Tawfik et al., 2014), grade (Pacheco et
al., 2013; Tawfik et al., 2014), lymph node invasion (Sturtz et al., 2014), and nodal
distribution (Chu et al., 2012). A study concluded that racial differences for clinical
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presentation (African American and Caucasian) were not observed among 493 TNBC
cases and for TNBC outcome, such as disease free survival and overall survival (Pacheco
et al., 2013). However, it needs to be emphasized that it was a retrospective single center
study (n=493) and the cases were diagnosed between 2006 and 2010 when better
treatment options (for disease outcomes) became available compared to the studies that
used data from the 1990s (Pacheco et al., 2013).
African American Women and Women from Other Ethnic Groups
When comparing African American women with women of other ethnicities,
non-significant differences were observed. Among Black and Hispanic women TNBC
tumors (compared to ER+ PR+ HER2- tumors) often present as 2- 4.9 cms in tumor size
compared to tumor size 1-5 millimetres (OR = 1.47, 1.20 respectively), and along with
these two groups, Asian Pacific Islanders have higher odds for tumor sizes more than 5
cms (OR = 1.93, 1.63, 1.63 respectively), all non-significant findings (p > 0.05) (Parise &
Caggiano, 2017). Similarly, for tumor grade, Black and White women have higher odds
for poorly differentiated tumors (OR = 55.35, 47.42 respectively) compared to Luminal A
subtype and Hispanic women along with Black women have higher odds for
undifferentiated tumors (OR = 63.37, 56.19 respectively) (p > 0.05) (Parise & Caggiano,
2017).
Iqbal, Ginsburg, Rochon, Sun, & Narod (2015) reported non-significant (p > 0.05)
ethnic differences among women diagnosed with TNBC tumors less than or equal to
2cms diameter using 18 SEER registries (n=53,577). Black women had the highest
proportion of 17.2% compared to 10.4% among South Asians (Asian Indian, Asian

36

Indian/Pakistani, or Pakistani), 10% among Hispanics, 8.8% for Chinese and 8.2% for
Japanese, and 8% among Non-Hispanic White (Iqbal et al.). Non-significant differences
reported between Black and White/other TNBC cases for histology (p = 0.969), stage (p
= 0.061), grade (p = 0.382), number of nodes (p = 0.467) (Dawood et al., 2009).
Hispanic women
Among Hispanic women, TNBC women compared with HR+HER2- subtype, were
approximately twelve times more likely to have a high tumor grade compared to low
tumor grades (p < 0.05) (Banegas et al., 2014). The same study reported a significant
association (p < 0.05) between tumor size and TNBC with approximately two-thirds of
the cases having tumor sizes >2 cms and higher odds observed for those with >5 cms at
diagnosis (OR = 1.59, 95% CI = 1.31-1.91) and between 2-5 cms (OR = 1.29, 95% CI
=1.14-1.45) compared to <2 cms HR+HER2- tumors (Banegas et al., 2014).
Genotype of Triple Negative Breast Cancer
BRCA 1/2 Mutations
Four studies done among TNBC cases reported prevalence of BRCA mutations
(Lynce et al., 2015; Gonzalez-Angulo et al., 2011; Sharma et al., 2014; Rummel et al.,
2013). Lynce et al. (2015) reported 21.4% of TNBC cases (n=211, four in BRCA1 and
two in BRCA2) to have deleterious mutations, in a breast cancer study sample with young
Black women only. Another study (n=207) reported deleterious BRCA1 mutation
prevalence of 11.1% and 4.3% for BRCA2 (Sharma et al., 2014). Gonzales-Angulo et al.
(2011) reported an incidence of 15.6% for BRCA1 (including one somatic TNBC case)
and 3.9% for BRCA2 mutations among 77 TNBC cases. Rummel et al. (2013) found a
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frequency of 9% clinically important BRCA1 mutations. The same group compared
BRCA1 mutation frequency based on significant risk factors and it was found that patients
with BRCA1 mutation along with risk factors had higher frequency compared to those
without significant risk factors (Rummel et al., 2013). For women aged < 60 years,
BRCA1 frequency was 11.2-18.3% for those with risk factors versus 4.6% without risk
factors; for women > 60 years of age, BRCA1 frequency 3.5%-7.7% with risk factors
versus 2.3% without risk factors (Rummel et al., 2013). See Appendix D for research
publication that address clinically important BRCA1 mutations (deleterious mutations)
and ethnicity in detail. Risk factors were based off the Hereditary Breast and Ovarian
Cancer Syndrome Testing criteria by the National Comprehensive Cancer Network
(Rummel et al., 2013) and Appendix E for copyright permissions from Rummel et al.,
2013.
BRCA mutations and TNBC. Studies reports significant higher proportion of
TNBC cases among BRCA mutation carriers. Pal et al. (2015) reported a mutation among
30% of TNBC cases compared to 7.1% of ER+ positive cases among women less than 50
years of age. TNBC cases significantly approximately three times higher among BRCA
carriers versus non-carriers (Pal et al., 2015). Eight studies assessed for BRCA1/2
prevalence in relation to ethnicity (Greenup et al., 2013; Rummel et al., 2013; Rao et al.,
2011; Pal et al., 2015; Lagos-Jaramillo et al., 2011; Nahleh et al., 2015; Bayraktar et al.,
2015; Gonzalez-Angulo et al., 2011). Rummel et al. (2013) assessed for BRCA1/2
mutations in their cohort of 182 women and reported 38% of their BRCA carriers were
African-American and more than 85% of the BRCA carriers were diagnosed less than 60
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years. Dean et al. (2015) reported two of the seven deleterious mutations in a Hispanic
sample to be TNBC, a non-significant finding (29%). One of the seven reported was a
newly described allele, 6005delT in BRCA 2 (Dean et al., 2015).
BRCA mutations among races/ethnicities. Among Hispanic women with Mexican
descent, 61% of BRCA mutation carriers compared to 28.6% among non-BRCA carriers
were TNBC, p = 0.014 (Nahleh et al., 2015). Greenup et al. (2013) conducted a study
among TNBC cases, who came for genetic counselling. They found that BRCA
prevalence significantly differed between races and by age at diagnosis (Greenup et al.,
2013). Ashkenazi Jewish women had the highest percentage (50%), followed by
Caucasian (33%), Asian/East Asian (29%), African American (21%), and
Latina/Hispanic (20%) (Greenup et al., 2013). However, Gonzales-Angulo et al. (2011)
report that significant differences in incidence of BRCA 1/2 mutation was not observed
between Black, Hispanic, White and others.
Pal et al. (2013) found a 6.5% prevalence for BRCA mutation among
African-Americans with early onset breast cancer (n=46). Among Hispanics and
Non-Hispanic Whites, BRCA1 mutation carriers were majorly TNBC (Lagos-Jaramillo et
al., 2011). Similar findings reported by Nahleh et al. (2014) on Hispanic women with
Mexico as country of origin. A majority, 85% of the BRCA1 carriers, presented with
TNBC compared to 27% of non-BRCA1 carriers (p < 0.001) (Nahleh et al., 2015). The
same study reported that none of the BRCA 2 carriers were TNBC compared to 37%
among non-BRCA2 carriers (Nahleh et al., 2015). Rao et al. (2011) documented a 4%
(n=50) incidence of BRCA mutation among Asian Indian American women who
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presented with stages 0, I, and II and it is not stated if these women were TNBC or not.
BRCA1 carriers were more likely to have TNBC than BRCA2 carriers, a non-significant
finding reported by one study (Bayraktar et al., 2015).
Among TNBC cases, BRCA carriers and women with wild-type BRCA1 was
assessed for clinic-pathologic tumor characteristics (Gonzalez-Angulo et al., 2011;
Rummel et al., 2013; Sullivan et al., 2014; Lagos-Jaramillo et al., 2011), ethnic
differences were not noticed (Rummel et al., 2013), but BRCA1 mutation carriers were
significantly younger in age (Rummel et al., 2013). Studies reported no significant
differences in age at diagnosis (Lagos-Jaramillo et al., 2011), patient outcomes (disease
free survival, recurrence, dead of disease, and dead of other causes frequency) (Rummel
et al.; Sullivan et al., 2014), lymph node status (Rummel et al., 2013), histology
(Gonzalez-Angulo et al., 2011; Lagos-Jaramillo et al.), tumor size (Rummel et al., 2013;
Lagos-Jaramillo et al., 2011), nuclear grade (Gonzalez-Angulo et al.; Lagos-Jaramillo et
al.) tumor stage (Rummel et al.; Sullivan et al., 2014; Gonzalez-Angulo et al.), tumor
grade (Rummel et al.), and BMI (Lagos-Jaramillo et al.) between BRCA mutation
carriers and wild-type TNBC cases.
BRCA 1/2 mutation and age at diagnosis. Younger age at diagnosis is associated
with BRCA mutations (Greenup et al., 2013; Nahleh et al., 2015; Sharma et al., 2014;
Sullivan et al., 2014; Rummel et al., 2013; Lynce et al., 2015; Gonzalez-Angulo et al.,
2011). Women aged less than 50 years at diagnosis had a high prevalence of BRCA 1
mutations compared to women between 51 and 60 years of age (27.6% vs 11.4%, p =
0.0007) (Sharma et al., 2014). Nahleh et al. (2014) reported that a majority (72%) of
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BRCA mutation carriers were less than 50 years of age when they presented with breast
cancers. This was a non-significant (p = 0.638) finding. The Greenup study found 84% of
women less than 40 years of age had a BRCA1 mutation and TNBC was significantly
associated with age at diagnosis (Greenup et al., 2013). A declining trend was observed in
the percentage of BRCA mutation positive cases for women age less than 40 years to
women above 70 years (44% versus 17%, respectively) (Greenup et al., 2013).
Studies consistently reported that when compared to sporadic cases, women with
TNBC and BRCA mutation(s) are significantly younger at clinical presentation
(average age), 45.8 years versus 54.8 years (Sullivan et al., 2014; Rummel et al., 2013),
45 years versus 53 years (Gonzalez-Angulo et al., 2011), 43 years versus 51 years
(Dean et al., 2015), 41.6 years versus 51.4 years (Lynce et al., 2015) and 40.2 versus
55.7 years for BRCA1 (p < 0.0001) and non-significant difference (p = 0.14) with
BRCA2 (Sharma et al., 2014).
Other gene mutations and Variants of Uncertain Significance
Mutations in other genes and Variants of Uncertain Significance (VUS) were
reported by four studies. One study (n=103) reported that among African American
women, 25% of those with deleterious mutations were TNBC and the four genes
associated were CHEK2, PALB2, ATM, and PTEN while the remaining 50% were in the
BRCA 1/2 genes (Churpek et al., 2015). Sharma et al. (2014) observed VUS only in 3.4%
of the study participants. However, Rummel et al. (2013) documented cases with VUS in
18% of study patients; Pal et al. (2013) reported VUS in 34.8% of the African American
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study sample; and 2 cases with VUS reported by Churpek et al. (2015), one in BRCA1
and another in BRCA2.
Single Nucleotide Polymorphisms (SNPs)
Three studies reported their findings on SNPs related to TNBC (Han et al., 2015;
Haiman et al., 2011; Palmer et al., 2012). Palmer et al. (2012) reported two SNPs,
rs10069690 in 5p13.33 (TERT gene) and rs8170 in 19p13.11 (TERT gene), to be
significantly (p = 0.02, 0.04 respectively) associated with TNBC. Han et al. reported
SNPs in 10q26/FGFR2 location (rs1219648) and 2q33/CASP8 (rs1045485) to be
significantly (p < 0.05) associated with TNBC. Another SNP reported at the
TERT-CLPTM1L locus on chromosome 5p15 (rs10069690) found to be significantly
associated with TNBC (p = 1.1X10-9) (Haiman et al., 2011; Palmer et al., 2012) in
women less than 50 years of age (Haiman et al., 2011). Palmer et al. further documented
that rs10069690 and rs8170 had significantly (p = .008) higher risk for developing TNBC
among African Americans only. Of note, the frequency of this allele is significantly [p =
1.1 X 10 (-9)] higher in women with African ancestry compared to European ancestry
and this highlights the role of genetic susceptibility in the incidence of TNBC (Haiman et
al., 2011).
Risk factors Similarities and Differences Among Ethnicities
Information about risk factors was synthesized from studies that compared TNBC
to Non-TNBC cases, most commonly HR+HER2- subtype, or with controls.
Contradictory findings have been reported for many variables and each will be reviewed
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in detail in the following sections. Refer to Table 2.4 for findings related to demographic
risk factors from the literature.
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Table 2.4
Literature Citing Demographic Risk Factors for TNBC
Demographic
Risk Factors

Studies with reported
significant finding (p < 0.05)

Race/ethnicity

Plasilova et al., 2016

Studies with reported
non-significant finding (p >
0.05)
Zaky et al., 2011

Tao et al., 2015

Swede et al., 2011

Sineshaw et al., 2014

Telli et al., 2011

Kanaan et al., 2014

Hines et al., 2011

Boone et al., 2014

Lagos-Jaramillo et al., 2011

Clarke et al., 2012

Trivers et al., 2009

Lin et al., 2012

Lund et al., 2008

Telli et al., 2011

Borderline significance

Lund et al., 2010

Dolle et al., 2009

Kwan et al., 2009
Stead et al., 2009
Morris et al., 2007
Llanos et al., 2015

Family History

Matt, Mozayen, Gress, & Tirona,
2015
Phipps et al., 2011
Shinde et al., 2010
Dolle et al., 2009
Borderline significance
Ambrosone et al., 2014
Country of

Ambrosone et al., 2014

Banegas et al., 2014

Origin

Telli et al., 2011

Age at

Parise & Caggiano, 2017

Ambrosone et al., 2014

Diagnosis

Plasilova et al., 2016

Zaky et al., 2011
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Table 2.4 (continued)
Chen et al., 2016

Dolle et al., 2009

Orucevic et al., 2015

Stead et al., 2009

Matt et al., 2015
Llanos et al., 2015
Banegas et al., 2014
Ambrosone et al., 2014
Sineshaw et al., 2014
Tawfik et al., 2014
Anders et al., 2011
Shinde et al., 2010
Santebennur et al., 2008
Brown et al., 2008
Kwan et al., 2009
Lund et al., 2008
Bauer et al., 2007
Socio-Economic Parise and Caggiano, 2017
Status

Parise and Caggiano, 2017

Llanos et al., 2015

Akinyemiju, Pisu, Waterbor, &

Banegas et al., 2014

Altekruse, 2015

Chu et al., 2012

Howlader et al., 2014

Trivers et al., 2009

Zaky et al., 2011

Brown et al., 2008

Telli et al., 2011
Lund et al., 2010

Education

Llanos et al., 2015

Dolle et al., 2009
Trivers et al., 2009

Insurance

Sineshaw et al., 2014

Llanos et al., 2015
Banegas et al., 2014
Telli et al., 2011
Trivers et al., 2009
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Country of origin
Three studies reported associations between country of birth and TNBC. Ambrosone
et al. (2014) compared TNBC cases with controls to show a significantly higher TNBC
proportion for women whose country of origin was foreign-born., 72% of U.S. origin and
19% of Caribbean origin were TNBC vs 81% were U.S.-born women and only 14% were
for Caribbean origin in controls, p = 0.04. Bangeas et al. (2014) used data on Hispanic
female residents diagnosed between 2005-2010 from CCR and reported 46.8% of TNBC
women to be U.S.-born and 53.2% to be foreign-born. Additionally, the same group
reported non-significant odds (p = 0.97) for TNBC among foreign-born versus U.S.-born
women (Banegas et al., 2014). Telli et al. (2011) investigated association of TNBC with
nativity (foreign born versus U.S.-born) and documented significant differences in
subtype distribution among Asian women (Chinese, Japanese, Filipina, Vietnamese,
Korean, South Asian, East Asian, and others) (p < 0.0001). Of all U.S. -born women in
the study sample (n=8140), 11% had TNBC and 12% of the Foreign-born had TNBC
(Telli et al., 2011).
Race/Ethnicity
More than thirty studies have reported associations between race/ethnicity and TNBC.
Among TNBC cases, Parise and Caggiano (2017) reported White had the highest
frequency of 57.1%, followed by Hispanics 21.1%, Blacks 11.7%, and Asian/Pacific
Islander 10.2%. Kurian, Fish, Shema, & Clarke (2010) projected a life-time risk to
develop TNBC for women of ethnicities in the following order: White, Black, Hispanic,
and Asian with the assumption that the women in the study were cancer free at age 40.
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Black women had the highest probability of developing TNBC followed by Whites,
Hispanics and the least was for Asian/Pacific Islanders (Kurian et al., 2010).
Black or African American women. Black women have the highest frequency of
TNBC compared to other races (Ricks‐Santi & McDonald, 2016; Llanos et al., 2015;
Chen et al., 2016; Chen &Li, 2015; Tao et al., 2015; Matt et al., 2015; Rana, 2009; Lund
et al., 2008; Santebennur et al., 2008; Kwan et al., 2009; Sineshaw et al., 2014; Lund et
al., 2009; Cui et al., 2014; Loo et al., 2011; Phipps et al., 2011; Sparano et al., 2012; Lin
et al., 2012; Sturtz et al., 2014; Bauer et al., 2007; Iqbal et al., 2015; Shinde et al., 2010;
Wright et al., 2012; Morris et al., 2007; Brown et al., 2008; Stead et al., 2009). Several
studies show Black women lead with the highest frequency for TNBC followed by
Hispanics and White (Parise & Caggiano, 2013; Howlader et al., 2014). Other studies
found African American women compared to Caucasians to have significant higher odds
for TNBC (Sineshaw et al., 2014; Lin et al., 2012; Kwan et al., 2009) and the frequency
to be twice as high compared to White patients (Tao et al., 2015; Lund et al., 2010;
Morris et al., 2007), to be three times more likely to develop TNBC (both p < 0.0001)
(Stead et al., 2009) and to have significantly higher rate of TNBC at all ages, p < 0.05
(Clarke et al., 2012). Tao et al. (2015) showed African-American women, when
compared to White women, with Stage III TNBC had a 37% risk of breast cancer death
(Tao et al., 2015). When TNBC was compared to ER positive tumors, African American
women had a significantly higher rate of cancer recurrence (60% versus 20%, p < 0.05)
along with significant lower rate of survival (47% versus 87%, p < 0.05) (Kanaan et al.,
2014). Non-significant (p > 0.05) findings were reported by few studies (Zaky et al., 2011
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Lund et al., 2008; Swede et al., 2011; Trivers et al., 2009). Compared to Non-African
American women or White women, African American/Black women had a three-fold
prevalence for TNBC (Lund et al., 2008), three times more likely to develop TNBC
tumors (multivariate OR =2.93) (Swede et al.), and almost three times more likely to
develop TNBC versus the Luminal Type A subtype (Trivers et al.).
Hispanic Women. TNBC is the second most common BC subtype among Hispanics,
following HR+HER2- subtype, with a frequency of 15.6%, a California Cancer Registry
dataset study (n=16,380) (Banegas et al., 2014) and 23.9% (n=309) in an affiliated county
hospital study (Khan et al., 2009). Hispanics when compared to NH Whites were 17%
more likely to have TNBC versus HR+/HER2- subtype (Sineshaw et al., 2014). Parise
and Caggiano (2017) reported higher odds for TNBC among Hispanic women aged 50-59
years when compared to women of the same age from Black and Asian Pacific Islander
ethnicities. Compared to NH White women, Hispanic women had statistically significant
differences in frequency of TNBC (16.4% versus 5.9% respectively, =0.0005) (Boone et
al., 2014). There was a statistically significant (p < 0.001) higher proportion of African
American and Hispanic women with TNBC compared to other BC-subtypes, but not with
API women (Bauer et al., 2007). Other studies reported Hispanics to have non-significant
(p > 0.05) higher proportion of TNBC compared to NH White (Lagos-Jaramillo et al.,
2011; Hines et al., 2011).
Asians or Asian/Pacific Islander Women. Multiple studies report TNBC cases
among sub-ethnicities in the Asian population (Parise & Caggiano, 2014; Parise &
Caggiano, 2016; Telli et al., 2011 Plasilova et al., 2016; Brown et al., 2008; Lin et al.,
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2012; Bauer et al., 2007). Parise and Caggiano (2016) used CCR data to investigate the
differences in TNBC frequency among White and Asian subgroups with a reported
frequency to be highest among the Indian subcontinent populations (Asian Indian,
Pakistani, Bangladeshi, Nepalese, Sikkimese, and Sri Lankan), followed by Korean,
Southeast Asian (Vietnamese, Laotian, Hmong, Cambodian, Thai, and Burmese), and
Whites (17.4%, 15.6%, 12% and 11.4% respectively). Pacific Islander had 10.9%
followed by Chinese (10.6%), Japanese (10%) and the least among Filipino women
(8.9%) (Parise & Caggiano, 2016). See Appendix F for email confirmation of a journal
article submission on breast cancer incidence among Asian Indian American women in
the United States versus women in India.
Plasilova et al. (2016) analysed cases from the National Cancer Database targeting
cancers reported 2010-2011. Compared to White women, Black, American
Indian/Eskimo, and Asian Indians had significantly (p < 0.001, 0.008, 0.003 respectively)
higher TNBC incidence and Filipino had significantly (p = 0.001) lower incidence
(Plasilova et al.). Compared with other ethnic women from the API group, women from
the Indian continent had 25% more likelihood to develop TNBC, while Chinese and
Filipino women were less likely (20% and 35%, respectively) (Parise & Caggiano, 2014).
When API women were compared to White women there was a lesser probability to
develop TNBC, but when API women were categorized and then analysed, Blacks had
the highest frequency (24.9%) followed by women from Indian Continent (16.5%),
Hispanics (16.2%), American Indian (14.9%), Korean women (14.7%), South East Asian
(12%), Pacific Islander (10.6%), Chinese (10.4%), Japanese (10.1%), and Filipino (9.6%)
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(Parise & Caggiano, 2014). The Indian continent women included Asian Indian, Pakistani,
Bangladeshi, Nepalese, Sikkimese and Sri Lankan (Parise & Caggiano, 2014).
TNBC frequency was 21% among the Asian Indian American women population
with stages 0, I, and II cancers (n= 50) (Rao et al., 2011). When NH White women are
compared with the Asian for the risk of developing TNBC, non-significantly (p > 0.05)
high odds ratios were found for the South-Asian women (OR = 1.3) followed by Korean
(OR = 1.2). A decreased risk was identified for Chinese (OR = 0.8) and Filipina (OR =
0.7) (Telli et al., 2011). This study used the data from California Cancer Registry (n=89
009) and showed TNBC frequency among all breast cancers for each Asian group as: 18%
for South Asian, 15% for Korean, 14% for Vietnamese, 11% for Chinese, 10% for
Filipina, 11% for Japanese compared to 12% for NH White. All groups were significantly
(p < 0.0001) different from NH White except Japanese (Telli et al., 2011).
Of all TNBC cases in the study sample, 76% were Caucasians, 13% were African
American, 7% were Hispanics, and 3% Asian Pacific Islander (Lin et al., 2012). Two
studies using data from California Cancer Registry compared TNBC to other cancers and
reported an overall TNBC frequency to be high among NH White women, then Hispanics
and NH Black, (Bauer et al., 2007; Brown et al., 2008). Frequencies of 62.2% for NH
White, 18.6% for Hispanics, 10% for NH Black, 8.4% for API and 0.8% for others were
also reported (Bauer et al., 2007). Borderline significance (p = 0.05) between TNBC
versus non-TNBC and race was reported by Dolle et al. (2009).
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Family History
Bethea et al. (2016) reported association of TNBC with family history of breast
cancer (OR = 1.72 versus 1.67 for ER-) and for an African American woman who has a
first degree relative with cervical cancer to have TNBC (OR = 3.04). The same study also
reported higher odds for TNBC with family history of ovarian cancer (OR = 1.53)
(Bethea et al., 2016). Six studies reported family history to be not significantly (p > 0.05)
associated with TNBC (Llanos et al., 2015; Matt, Mozayen, Gress, & Tirona, 2015;
Phipps et al., 2011; Rana, 2009; Shinde et al., 2010; Dolle et al., 2009) and only one
study reported borderline significance, with 18% of cases with positive family history, p
= 0.05 (Ambrosone et al., 2014). Family history as a risk is reported by five studies along
with BRCA mutation (Rummel et al., 2013; Lynce et al., 2015; Sharma et al., 2014;
Churpek et al., 2015; Gonzalez-Angulo et al., 2011). Lynce et al. (2015) reported a
significant family history in 83.3% of TNBC mutation carriers versus 47.1% among
TNBC non-carriers. Rummel et al. (2013) in their sample of 182, reported 25% of TNBC
cases to have family history of breast and/or ovarian cancer. A study reported BRCA
mutation prevalence as 31.6% for women with TNBC and significant family history/SFH
when compared to 6.1% for TNBC women without SFH (Sharma et al., 2014). SFH is
when there is a positive history for a breast cancer less than 50 years of age in the family
or an ovarian cancer (Sharma et al., 2014). The study population of Sharma et al. (2014)
includes the major race/ethnic groups however analysis was not carried out to see
differences between races.
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The proportion of deleterious mutations in familial TNBC cases was high compared
to non-familial TNBC cases, but not a statistical significant finding (34% vs 14.9%, p =
0.071) (Churpek et al., 2015). Another study reported 14 germline mutations among
TNBC cases and only five of them had a first degree relative with breast and /or ovarian
cancer, no further comparison details are provided (Gonzalez-Angulo et al., 2011).
However, Dean et al. (2015), reported a non-significant difference in frequency of family
history between BRCA carriers and non-carriers.
Age at Diagnosis
TNBC tumors occur primarily at younger ages with significant findings (p < 0.05)
reported by seventeen studies (Parise & Caggiano, 2017; Plasilova et al., 2016; Matt et al.,
2015; Chen et al., 2016; Llanos et al., 2015; Orucevic et al., 2015; Banegas et al., 2014;
Ambrosone et al., 2014; Bauer et al., 2007; Santebennur et al., 2008; Kwan et al., 2009;
Sineshaw et al., 2014; Brown et al., 2008; Shinde et al., 2010; Anders et al., 2011; Lund
et al., 2008; Tawfik et al., 2014). Women less than 40 years old had a high frequency of
TNBC (19.7%) (Sineshaw et al., 2014). The mean age at diagnosis was lower among
TNBC women compared to Luminal A subtype (56.7 years versus 60.6 years respectively)
(Parise & Caggiano, 2017). Another study reported a mean age of 52 years for TNBC, 61
years for HR+HER2- tumors and 56 years for HER2 overexpression tumors (p = 0.01)
(Lund et al., 2008). When compared to non-TNBC cases the median age at diagnosis is
significantly lower in TNBC cases: 51 versus 57 years respectively, p < 0.001 (Tawfik et
al., 2014), 54 years vs 60 years, p < 0.001 (Bauer et al., 2007; Brown et al., 2008), 54.5
years versus 59.3 years, p < 0.001 (mean age in Caucasian women only study) (Orucevic
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et al., 2015). Only one study reported 56 years and it was not significantly different than
Non-TNBC tumors (Maiti, Kundranda, Spiro, & Daw, 2010).
Parise and Caggiano (2017) used data from the California Cancer Registry and
showed that White and Hispanic women aged 30-39 years had higher odds (1.37 and 1.35
respectively) for TNBC compared to women aged 50-59 years of same race/ethnic origin.
Additionally, invasive breast cancer cases less than 50 years of age was double among
TNBC compared to Luminal A subtype (Parise & Caggiano, 2017). One study identified
a statistically significant (p = 0.0197) finding that three-fourths of TNBC sample was
above the age of 45 years compared to other sub-types (Llanos et al., 2015). The average
age at diagnosis for TNBC woman was 54 years and the age range was 29-91 years in a
sample collected for the Clinical Breast Care Project (n=182) (Rummel et al., 2013) and
the median age reported was 58 years compared to 60 years for HR+ and HER2+ cancers
(Matt et al., 2015). TNBC is significantly associated with younger aged African
American women (<40 years) when compared with non-African American older women
(64% versus 29%, p = 0.03) (Anders et al., 2011). Despite the association of TNBC with
younger age, the age-specific incidence rate is found to peak in the later years of life. A
study using the SEER registry published that age-specific incidence rates for TNBC peak
in the age groups 60-74 years (Amirikia et al., 2011).
Parise and Caggiano (2017) in their large sample (TNBC, n= 19,283) noted that 50%
of the Black women and 41% of the Hispanic who were less than 40 years had TNBC.
Significant differences exist between ethnic groups (White, Black, API) for incidence rate
ratios based on age at diagnosis, p < 0.05 (Clarke et al., 2012). Breast cancer incidence
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rates for women less than 45 years of age at diagnosis were higher for Black women
compared to White women (133.7 versus 129.2 per 100,000 woman-years respectively),
and vice versa for women above 50 years of age (Clarke et al., 2012). Among TNBC
cases, African American women had a significantly younger mean age at diagnosis
compared to Caucasian women, 52.28 years versus 59.06 years respectively, p = 0.002
(Sullivan et al., 2014). Banegas et al. (2014) reported significantly lesser risk for Hispanic
women at ages 45-49 years compared to Hispanic women aged 50-54 years for TNBC
risk, p < 0.05. For Non-Hispanic Black women, age-specific incidence rates for TNBC
peak in the age group 65-69 years (Howlader et al., 2014). Three studies reported no
significant differences between African American and Caucasian TNBC women for age
at diagnosis, p > 0.05 (Chu et al., 2012; Sturtz et al., 2014; Dawood et al., 2009).
Non-significant, p > 0.05 associations between age at diagnosis and TNBC was found in
four studies (Stead et al., 2009; Ambrosone et al., 2014; Zaky et al., 2011; Dolle et al.,
2009). Dolle et al. sample had included women less than 45 years of age only. Few
studies report higher risk for younger aged TNBC women compared to HR+HER2cancer, but these were non-significant findings (Lund et al., 2008; Lund et al., 2010; Telli
et al., 2011).
Socio Economic Status (SES)
Studies with reported findings related to TNBC associations with the variables
income level, poverty level, insurance status, and education are discussed in this section.
Significant associations between SES and TNBC were reported by three studies (Llanos
et al., 2015; Brown et al., 2008; Banegas et al., 2014). Data from CCR for years

54

2000-2013 showed proportions of TNBC women to be high in lowest SES quintile versus
Luminal A subtype (14.7% versus 10.3% respectively) and low in highest SES quintile
(23.3% versus 29.8% in Luminal type A) (Parise & Caggiano, 2017). State median
income of less than $70,000 and education level below college indicated lower SES in a
study, and TNBC was found to have significant (p < 0.05) higher odds for these two
categories when compared to Luminal A subtype (Llanos et al., 2015).
A high frequency of TNBC women were found in low SES compared to high SES in
a study conducted using California Cancer Registry (Sineshaw et al., 2014, Parise and
Caggiano, 2014). Four studies reported ethnic differences for SES among TNBC cases
(Parise & Caggiano, 2017; Sineshaw et al., 2014; Parise & Caggiano, 2017; Banegas et
al., 2014; Chu et al., 2012). White and Hispanic women from low SES showed an
increased risk for TNBC, for Black women non-significant association (p > 0.1.99) was
observed, whereas for API women SES did not make any difference (Parise & Caggiano,
2017). Among low SES (a composite variable using insurance status and area-level
median income quartile, used by Sineshaw et al., 2014), compared to NH White, NH
Black and Hispanic are more likely (79% and 19%, respectively) and API are 20% less
likely to be TNBC (Sineshaw et al., 2014). However, NH Black had similar higher odds
even in the high-status strata compared to NH White (Sineshaw et al., 2014). Among
Hispanic women, Banegas et al. (2014) reported significant associations between lower
SES and TNBC cases and 1.32-1.42-fold increased risk for TNBC compared to
HR+HER2- subtype (p < 0.005). Among TNBC cases, Chu et al. (2012) documented
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significant differences between African American and Caucasian women for mean annual
income and Caucasian women earned more than African American women (p < 0.001).
Statistically non-significant (p > 0.05) odds for SES and TNBC were reported by six
studies (Howlader et al., 2014; Trivers et al., 2009; Zaky et al., 2011; Lund et al., 2010;
Telli et al., 2011). Different poverty indexes were used by these studies such as county
level poverty index, federally defined poverty level. Among all breast cancer cases,
TNBC women fall mostly into low SES compared to high and medium SES levels using
county level poverty index (14.8% versus 11.4% versus 12.6%, respectively) (Howlader
et al., 2014). Trivers et al. (2009) reported significant associations (p < 0.05), but
non-significant higher odds between TNBC and high (>700%) and low SES (<= 200%)
compared to middle poverty index (201%-700%). Zaky et al. (2011) reported
non-significant associations between TNBC tumors and SES (< or > than 20% of
federally defined poverty level). Akinyemiju, Pisu, Waterbor, & Altekruse (2015)
reported no association between SES and TNBC; the study employed the National
Cancer Institute’s SES index.
Significant associations were observed between TNBC and the educational level of
women. Llanos et al. (2015) compared TNBC to other BC subtypes and showed 57.1% of
women had less than college level education compared to 48.6% among Luminal A type
(p = 0.04). Ambrosone et al., reported for an AA sample only study, almost half (49%) of
the TNBC women had less than high school level education compared to 37% in controls.
Non-significant associations between education and TNBC reported by two studies
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(Dolle et al., 2009; Trivers et al., 2009) and no ethnic differences (Sturtz et al., 2014)
were reported for educational status.
Sineshaw et al. (2014) reported a significant (p < 0.0001) higher proportion of TNBC
cases among uninsured (15.8%) and Medicaid-insured (16.4%) compared to other
insurance types. Non-significant associations between TNBC and insurance status has
been reported (Llanos et al., 2015; Telli et al., 2011; Trivers et al., 2009; Banegas et al.,
2014). Two studies, Llanos et al., 2015 and Dolle et al., 2009 reported non-significance
between TNBC and income level (p = 0.3840; p = 0.55 respectively).
Hormonal Factors Related to TNBC
Refer to Table 2.5 for literature citing hormonal risk factors for TNBC.
Age at Menarche. Seven studies reported their findings on the association between
age at menarche and TNBC. Significant findings by one study (Shinde et al., 2010)
identified a borderline significance in one study (Dolle et al., 2009). Five other studies
identified no associations between these same variables (Llanos et al., 2015; Ma et al.,
2017; Trivers et al., 2009; Ambrosone et al., 2014; Phipps et al., 2011). Women with
TNBC significantly differed from non-TNBC by younger age at menarche, with a mean
age of (12.58+1.51y versus 12.75+1.53y (p = 0.03) (Shinde et al., 2010). Non-significant
ethnic differences were observed between African American and Caucasian women
(Sturtz et al., 2014).
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Table 2.5
Literature Citing Hormonal Risk Factors for TNBC
Hormonal
Risk Factors
Age at

Significant findings
(p < 0.05)
Shinde et al., 2010

Non-significant findings
(p > 0.05)
Ma et al., 2017
Llanos et al., 2015

Menarche

Ambrosone et al., 2014
Phipps et al., 2011
Trivers et al., 2009
Borderline significance
Dolle et al., 2009
Age at

Lin et al., 2012

Llanos et al., 2015
Sturtz et al., 2014

Menopause

Phipps et al., 2011
Hines et al., 2011
Shinde et al., 2010
Borderline significance
Ambrosone et al., 2014
Age at first

Ambrosone et al., 2014

Ma et al., 2017

live birth

Shinde et al., 2010

Phipps et al., 2011
Trivers et al., 2009
Dolle et al., 2009

Use of Oral

Bethea et al., 2015

Llanos et al., 2015

Contraceptive

Beaber et al., 2014

Ambrosone et al., 2014

Pill

Dolle et al., 2009
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Table 2.5 continued

Parity

Palmer et al., 2014

Ma et al., 2017

Phipps et al., 2011

Llanos et al., 2015

Shinde et al., 2010

Trivers et al., 2009
Dolle et al., 2009
Borderline significance
Ambrosone et al., 2014

History of

Phipps et al., 2011

Pregnancy

Dolle et al., 2009

Losses
Breastfeeding

Ma et al., 2017

Llanos et al., 2015

Shinde et al., 2010

Trivers et al., 2009

Kwan et al., 2009

Dolle et al., 2009

Note. Articles categorized by variables for hormonal risk factors associated with TNBC.
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Age at menopause. Significant risk for premenopausal women to develop TNBC
was reported by one study (Lin et al., 2012). Pre-menopausal women with high body
mass index was at a significantly higher risk for TNBC compared to post-menopausal
women (p value for interaction=0.02) (Lin et al., 2012). Another study reported
borderline significance associations between TNBC versus controls for Menopause, p =
0.05 (Ambrosone et al., 2014). Five studies reported no association (Llanos et al., 2015;
Phipps et al., 2011; Shinde et al., 2010; Hines et al., 2011; Sturtz et al., 2014). TNBC
frequency found to be higher in pre-menopausal status (<=50 years) versus
post-menopausal status (>50 years), although not statistically significant (Shinde et al.,
2010; Hines et al., 2011). No significant ethnic differences between African American
and others were documented for menopausal status in TNBC (Sturtz et al., 2014; Dawood
et al., 2009).
Age at first live birth. Two studies reported significant associations between age at
first live birth and TNBC risk (Ambrosone et al., 2014; Shinde et al., 2010). TNBC
women were reported to be significantly younger than non-TNBC women to have their
first live birth (mean age for TNBC was 22.48 years compared to 23.97 years for
non-TNBC women, p < 0.001) (Shinde et al., 2010). Ambrosone et al. also found
significant associations (p = 0.04) when TNBC cases compared with controls. Four
studies reported non-significant (p > 0.05) associations between TNBC and age at first
live birth (Ma et al., 2017; Trivers et al., 2009; Phipps et al., 2011; Dolle et al., 2009).
Trivers et al. found non-significant increased risk for women who had their first birth less
than 18 years of age when compared to HR+/HER2-. There were non-significant ethnic
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differences reported between African American and Caucasian TNBC women for these
variables (Sturtz et al., 2014).
Use of Oral Contraceptive Pill (OCP). Studies reported association between OCP
use and TNBC (Bethea et al., 2015; Dolle et al., 2009; Beaber et al., 2014). Compared to
controls, TNBC cases had higher odds associated with the self-reported use of OCP,
especially use within the previous 5 years and the risk significantly (p trend = 0.05)
declined as years increased (OR = 1.78) (Bethea et al., 2015). The longer the duration of
OCP use (more than or equal to one year) placed 2.5 times more likely at risk for TNBC
when compared to non-TNBC women and the risk was significantly higher (P
heterogeneity=0.008)

for women less than 45 years of age (Dolle et al., 2009). When

comparing TNBC women to other sub-types, OCP use for more than five years, among
women aged 20-39 years, had a non-statistically significant higher risk (3.7 times) for
TNBC (Beaber et al., 2014). However, Beaber et al. (2014) reported significant
association between every single year of OCP use and increase in risk for TNBC when
compared to ‘never use’ of OCP (p = 0.045). Two studies reported no significant
associations compared to controls (Llanos et al., 2015; Ambrosone et al., 2014).
Non-significant ethnic differences were observed between African American and
Caucasian women (Sturtz et al., 2014).
Parity. Nine studies identified a link between parity and TNBC. Three of these
studies found significant associations between parity and TNBC (Shinde et al., 2010;
Phipps et al.2011; Palmer et al., 2014). Parous (two and three live births) women are at
significantly higher risk of developing TNBC compared to nulliparous women (Shinde et
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al., 2010; Palmer et al., 2014) and the risk increased by 37% for ever parous women
compared to non-parous women (Palmer et al., 2014). Ambrosone et al. (2014) found
borderline significance for higher odds of women with two or more live births to be
TNBC. Similarly, Phipps et al. found nulliparity women had a significantly decreased
risk for TNBC (p = 0.02). Four other studies found no association between parity and
TNBC (Llanos et al., 2015; Ma et al., 2017; Trivers et al., 2009; Dolle et al., 2009). No
associations reported between TNBC and history of pregnancy losses (Phipps et al., 2011;
Dolle et al., 2009).
Breastfeeding. Breastfeeding was found to be associated with TNBC (Shinde et al.,
2010; Ma et al., 2017; Kwan et al., 2009). TNBC women were more likely to have never
breastfed (Kwan et al., 2009). Ma et al. (2017) reported a decrease in TNBC risk with
increasing duration of breastfeeding (Ptrend=0.006) and a 31% decreased risk for parous
women who breastfed for at least one year compared to those who never breastfed.
Ambrosone et al. (2014) study reported a decreased risk for women who ever breastfed
compared to never breastfed and Palmer et al., 2014 reported a 19% decreased risk for
ever versus never lactation. Women who breastfed for >2 months per child had lesser risk
for developing TNBC compared to those who did not breastfeed and there is an inverse
relationship between the duration of breastfeeding and the occurrence of TNBC (Shinde
et al., 2010). Llanos et al. (2015), Trivers et al., Dolle et al. (2009) found no associations
between breast-feeding and TNBC. Phipps et al. found no associations between the
length of breastfeeding duration with TNBC risk.
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Significant ethnic differences were observed between African American and
Caucasian parous women with TNBC, a Caucasian woman were more likely to breast
feed (p < 0.001) (Sturtz et al., 2014). However, Ma et al., (2017) reported that age and
race modified the association between TNBC and breastfeeding. AA women who
breastfed 6 months or longer and between the ages 20-44 years were reported to have 82%
lesser risk for TNBC compared to their counterparts who never breastfed.
Obesity. Obesity was reported in the literature to have a significant (p < 0.05)
association with TNBC compared to ER/PR+HER2- and controls (Trivers et al., 2009).
Postmenopausal high and recent BMI was associated with decreased risk (Bandera et al.,
2015; Chen et al., 2016) but high BMI in premenopausal was reported to have different
findings. Bandera et al. reported no association of obesity with TNBC, but Chen et al.
(2016) and Kwan et al. (2009) found higher odds for TNBC among premenopausal obese
women. Premenopausal obese women had 82% increased risk for TNBC (Luminal A
referent) compared to women whose BMI was less than 25 Kg/m2 (Chen et al., 2016).
Inconsistent findings could be due to sample numbers, Chen et al. (2016) study sampled
2659 women aged 20-69 years from different ethnicities, whereas Bandera et al. studied
women from the AMBER consortium, only African American women (2,104 cases and
12,060 controls). Lin et al. found borderline significance (p = 0.052) for BMI differences
among TNBC cases. In their study women with BMI >30 kg/m2 was associated with
TNBC risk compared to BMI 25-30kg/m2 and <25 kg/m2 (Lin et al., 2012). No
associations between BMI and TNBC were reported by four studies (Llanos et al., 2015;
Stead et al., 2009; Dolle et al., 2009; Ambrosone et al., 2014). When assessed for ethnic
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differences among TNBC cases, AA women compared to White women were
significantly (p = 0.024) more likely to be obese (Sturtz et al., 2014). Elevated Waist Hip
Ratio had stronger association with TNBC (Bandera et al., 2015).
Hormone Replacement Therapy (HRT). Shinde et al. (2010) observed differences
between TNBC and non-TNBC cases for use of HRT and the duration of HRT use was
significantly less among TNBC cases (3.38 years versus 4.53 years, p = 0.002). Chen et
al. (2016) reported that TNBC women were more likely to be users of estrogen-only HRT
next only to Luminal A subtype (6.8% versus 4.6% respectively), however not a
statistically significant finding. Two studies found no associations between HRT and
TNBC (Llanos et al., 2015; Ambrosone et al., 2014). Among postmenopausal women,
non-significant ethnic differences observed between African American and Caucasian
TNBC women who used HRT (Sturtz et al., 2014).
Other Risk Factors
Other TNBC risk factors were studied with varying results. Smoking status identified
no significant (p > 0.05) associations reported by five studies, (Park et al., 2016; Rana,
2009; Dolle et al., 2009; Ambrosone et al., 2014; Trivers et al., 2009). The risk for TNBC
was significantly (p = 0.03) twice among African-American women compared to White
women for alcohol consumption of >7 drinks per week (Williams, Olshan, Tse, Bell, &
Troester, 2016) with Trivers et al. and Dolle et al. reported no association with alcohol
consumption. Trivers et al. reported no association with physical activity in the year
before cancer diagnosis (p > 0.05), Caffeine intake was identified as having ethnic
differences among TNBC cases (Sturtz et al., 2014). Among TNBC cases, safe/moderate
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intake (<500mg/day) of caffeine intake was high among African American women
compared to high/extremely high intake among Caucasian women (p < 0.001) (Sturtz et
al., 2014). Similarly, among TNBC cases alcohol consumption was significantly (p <
0.05) less for African American women compared to Caucasian women), but smoking
and physical activity did not differ significantly (p = 0.757, 0.138 respectively) between
African American and Caucasian women (Sturtz et al., 2014).
Non-significant associations between marital status and TNBC was reported by a
study (Llanos et al.). Another study reported non-significant (p = 0.671) ethnic
differences observed between African American and Caucasian TNBC women for
marital status (Sturtz et al., 2014). Llanos et al. (2015) reported women with TNBC
tumors to be less likely (OR = 0.6) to have history of benign breast disease compared to
Luminal A subtype, but no association was reported by Ambrosone et al.
Maiti et al. (2009) identified an association between TNBC and Metabolic syndrome.
When compared to Non-TNBC a higher percentage of TNBC women had a Metabolic
syndrome diagnosis (36.7% versus 58.1% respectively, p = 0.004) based on the National
Cholesterol Education Program (Maiti et al., 2009). Similar results were observed from
information based on a study by the American Association of Clinical Endocrinologists
(52.3% in TNBC versus 34.3% in Non-TNBC, p = 0.017) (Maiti et al., 2009).
Ethnic Differences in Prevention, Early Detection, and Treatment
Prevention of TNBC
In regards to prevention of TNBC, few studies discussed genetic testing and
counseling (Ricks‐Santi & McDonald, 2016; Thompson et al., 2012; Lynce et al., 2015;
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Armstrong et al., 2015; Cragun et al., 2015; Sussner et al., 2009). Healthcare provider
referral and race/ethnicity were documented to be significant factors in having germline
genetic testing (Cragun et al., 2015; Thompson et al., 2012).
Factors associated with receiving genetic counseling and healthcare provider referral
for genetic testing were investigated in two studies. The variables of healthcare provider
referral, household income >$35,000 in the year prior to diagnosis, and insured with a
private health insurance were strongly associated with receiving genetic counseling
(Cragun et al., 2015). The study by Cragun et al. was conducted among 440 Black
women with age at diagnosis <50 years. The variables that were associated with a
healthcare provider referral were college education (Cragun et al., 2015; Armstrong et al.,
2015), age at diagnosis less than 45 years of age (Thompson et al., 2012; Cragun et al.,
2015), NH White (Armstrong et al., 2015), married (Armstrong et al., 2015), higher
incomes (Armstrong et al., 2015) and TNBC status (Cragun et al., 2015). Younger age at
diagnosis (<50 years) had significantly five times higher odds (p < 0.001) of getting
tested for BRCA compared to women aged >50 years (Vig et al., 2013). Cragun et al.
indicated that socioeconomic factors and healthcare provider referrals may possibly
contribute to the genetic services access disparities among underserved minority
population.
The American BRCA Outcomes and Utilization of Testing (ABOUT) study found
that lower rates of genetic counseling prior to testing was lowest among patients of
obstetricians/gynaecologists (Armstrong et al., 2015). Similarly, the women in an
oncology setting were significantly likely to receive physician recommendation for
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germline genetic testing and counseling compared to other recruitment methods such as
research contact database, genetic counselor, and community groups (p = 0.03,0.03,
0.0001, respectively) (Thompson et al., 2012). Sussner’s research group (2009) assessed
for predictors of intention for genetic counseling and showed that at-risk Latinas with
“competing life concerns” were significantly less likely to undergo BRCA genetic
counseling, p = 0.0002 (Sussner et al., 2009). Other documented significant predictors of
the intention to genetic counseling were the perceived risk of carrying a BRCA mutation
and referral by their physician (Sussner et al., 2009). Other non-significant predictors for
the intention to make an appointment in the next 6 months were positive attitudes about
genetic counseling, age, personal diagnosis of breast cancer, and family history of breast
cancer in a first degree relative (Sussner et al., 2009).
Physician recommendation for genetic testing and counseling was reported to be
significantly lower among less educated Black women (high-school degree or less),
Black women with no insurance and foreign-born Black women (Thompson et al., 2012).
This study, conducted among African American only (n=125 and 40% born outside The
United States), found statistically significant (p = 0.03) independent associations between
younger women (<45 years of age) and physician recommendation for genetic counseling
(Thompson et al., 2012). Thompson et al. (2012) recommended development of specific
interventions for Black women for all ages to reduce racial disparity. Han et al. (2015)
suggested the development of a risk assessment model based on the Genetic Risk
Assessment Score and other risk factors to identify women high risk for breast cancer.
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MacNew, Rudolph, Brower, Beck, & Meister (2010) recommended educational
efforts on BRCA testing and its benefits to be focussed on less educated and minority
groups. Statistical associations were found between knowledge about breast cancer genes
and ethnicity, but not with age and religion by MacNew et al. (2010). Among Caucasians,
African Americans, and Hispanic/others it was found that a higher proportion of
Caucasians than the other ethnic groups had the knowledge of breast cancer genes (67.3%,
p = 0.000) (MacNew et al., 2010). Similarly, women with graduate school education and
an income greater than $100 000 were statistically significant (p = 0.003, 0.022
respectively) in higher proportions to have knowledge about genetic testing and genes
compared to other levels of education (MacNew et al., 2010). Women with a positive
family history of breast cancer were at significantly higher odds of having knowledge
about the role of mutated genes in developing breast cancer and significantly (p = 0.001)
more likely to know about genetic testing, whereas having a personal history of breast
cancer did not have an impact on knowing genes, testing and choosing a genetic test (p >
0.05) (MacNew et al., 2010).
Early detection of TNBC
Findings from studies suggest that early identification of TNBC risk factors among
women and recommendation of genetic testing/counseling as well as regular screening
may help with early detection of TNBC (Sharma et al., 2014; Lin et al., 2012; Llanos et
al., 2015). Findings from the study by Sharma et al. (2014) also concluded that age at
TNBC diagnosis and significant family history were significant (p < 0.0001 for both)
predictors of BRCA mutation status. Llanos et al. (2015), reported that there are higher
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odds for TNBC tumors to be self-detected compared to Luminal A subtype (OR 2.7,
95%CI 1.7-4.2). Only 36.5% of Luminal A tumors were self-detected compared to 60.5%
of TNBC tumors (Llanos et al.). Lin et al. found that one-third of the TNBC patients
self-detect their tumors and a significantly smaller number of women clinically present
based on abnormal screening mammogram (29% vs 48%, p < 0.0001). Women with
TNBC present more often with symptoms when compared to those with HR+HER2cancers (68% vs 48%, p < 0.001) (Lin et al., 2012).
One study’s finding highlights the need for evaluation of risk factors in women
(</>60 years) and helps to identify TNBC women who may benefit from BRCA genetic
testing (Rummel et al., 2013). On comparing BRCA1 mutation frequency based on age
(less/more than 60 years) and significant risk factors, it was found that patients with
BRCA1 mutation along with risk factors had higher TNBC frequency compared to those
without significant risk factors (11.2-18.3% versus 4.6% for age <60 years and 3.5%-7.7%
versus 2.3% for age >60 years) (Rummel et al., 2013). Risk factors were based on the
Hereditary Breast and Ovarian Cancer Syndrome Testing criteria by the National
Comprehensive Cancer Network (Rummel et al., 2013).
TNBC Treatment
Plasilova et al. (2016) reported significant differences among types of breast cancer
for chemotherapy and surgery. There were 81.4% of TNBC cases that underwent
chemotherapy compared to 34.9% in HR+/HER2-, 75.2% in HR+/HER2+, and 84.5%
among HR-/HER2+. Among Breast Conservation Therapy patients, TNBC there were
significant differences from non-TNBC cases for use of chemotherapy (p = 0.007) and
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hormone therapy (p < 0.0001) and no differences for completion of radiotherapy (Zaky et
al., 2011). TNBC women were significantly more likely to receive chemotherapy (69.7%
versus 40% in non-TNBC cases, p = 0.007), and less likely for hormone therapy (3%
versus 79.4% among non-TNBC cases) (Zaky et al., 2011). There were no differences
noted for completion of radiotherapy between TNBC and non-TNBC tumors (Zaky et al.,
2011). Recurrence Free Survival at five years was significantly higher for TNBC women
with a BRCA mutation versus wild-type status, 86.2% versus 51.7%, p = 0.031
(Gonzalez-Angulo et al., 2011). No significant differences were identified between
African American and Caucasian TNBC women for systemic treatment obtained, but
significant differences (p = 0.01) for type of surgery (Mastectomy versus Breast
Conserving therapy) (Chu et al., 2012). There were 81% versus 63% who opted for
mastectomy among Caucasian and African American TNBC women, respectively (Chu et
al., 2012). Plasilova et al. (2016) reported that TNBC had significantly lesser odds for
surgery (p = 0.009) and chemotherapy (p < 0.001) treatments compared to HR+/HER2-.
Two studies compared African American and White/other women for patient
outcomes after primary systemic chemotherapy; only one found significant (p = 0.001)
ethnic differences (Balmanoukian et al., 2009). The study aimed at finding if racial
differences existed in pathologic Complete Response/pCR to treatment (Balmanoukian et
al., 2009). Among TNBC cases post Primary Systemic Therapy (PST) they found that
compared to White/other women (n=23), African American women (n=15) were more
likely to suffer recurrence and death and had less chances of achieving pCR, (13% versus
52% among White/other, p = 0.001) (Balmanoukian et al., 2009). Significant differences
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between African American and White/other women after PST exist for recurrence free
survival (p = .045) and overall survival (p = .028) and that both are shorter in duration for
African American women (Balmanoukian et al., 2009). However, Dawood et al. found no
significant differences (p = .302) between Black and White/others patients (only TNBC
cases who underwent primary systemic chemotherapy, n=471) in overall survival (OS)
and recurrence-free survival (RFS) and that race was not associated with survival
outcomes. They stated that pCR was not affected by race (Dawood et al., 2009). Dawood
et al. found no significant (p = .341) differences between African Americans and others
for the type of chemotherapy used (Taxane only, anthracycline only,
Taxane/anthracycline combination, and other), type of surgery (mastectomy versus
segmental), and radiotherapy usage (yes/no). More research is needed to assess the true
associations between race and survival outcomes after treatment (Balmanoukian et al.,
2009).
Summary
In summary, the literature review on TNBC provided the available incidence,
frequency of TNBC. The original search retrieved 900 articles and 85 articles were
selected for the review based on the selection criteria. It described the TNBC phenotypic
and genotypic traits and examined ethnic differences among TNBC phenotype and
genotype. Risk factors related to TNBC, ethnic differences for risk factors were stated.
Finally, ethnic differences for prevention, early detection, and treatment of TNBC were
discussed.
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Many knowledge gaps were identified when the last ten years’ literature were
reviewed. TNBC ranked next to HR+/HER2- in frequency and the most recent TNBC
incidence rate was published in 2014 and 2015. Mixed results (statistically significant and
non-significant) were observed from literature on phenotypic, demographic, and
treatment characteristics of TNBC tumors. Studies reported mutations mainly in BRCA 1/
2 and few other genes, Single Nucleotide Polymorphisms, and Variants of Uncertain
Significance. Risk factors that majorly contributed to TNBC were country of origin,
race/ethnicity, age at diagnosis, socio economic status, family history, BRCA mutations,
reproductive factors, obesity, hormone replacement therapy, and others. Research
questions were developed based on the identified gaps in the literature.
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CHAPTER 3
TNBC INCIDENCE RATES; PHENOTYPIC, DEMOGRAPHIC AND
TREATMENT CHARACTERISTICS OF TNBC
AMONG WOMEN OF COLOR
Submitted on 7/30/2017, Oncology Nursing Forum
Introduction
Triple Negative Breast Cancer (TNBC) is a breast tumor that lacks Estrogen
Receptor, Progesterone Receptor, and is Human Epidermal Growth Receptor 2/neu
negative (Goldhirsch et al., 2011). It has the worst breast specific and overall survival rate
(Lin et al., 2012), a higher proportion of local and distant metastasis rates (Zaky et al.,
2011), and is treated by Breast-conserving surgery (lumpectomy), neoadjuvant treatment,
and adjuvant systemic therapy (TNBC Treatment, 2017). Studies on TNBC have been
done predominantly on the Non-Hispanic White and Non-Hispanic Black population,
whereas Hispanic and Asian sub-groups have been understudied (Howlader et al., 2014;
Kohler et al., 2015; Llanos et al., 2015). TNBC statistics on Asian sub-groups can be
misleading as they are grouped under one race such as “Asian/Pacific Islander.” Although
literature has evidence of information on TNBC clinical behaviour on major racial groups
like Non-Hispanic White and Non-Hispanic Black (Chu, Henderson, Ampil, & Li, 2012;
Dawood et al., 2009; Pacheco, Gao, Bumb, Ellis, & Ma, 2013; Sturtz, Melley, Mamula,
Shriver, & Ellsworth, 2014; Sullivan et al., 2014), there is a lack of any large-scale study
that includes Asian sub-groups.
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Purpose of the Study
The problem statement and gaps in literature lead to the following research questions
and hypotheses.
Question and Research Hypothesis
a) Is there a difference in age-adjusted and age-specific incidence rates for TNBC
among races/ethnicities?
There will be significantly higher age-adjusted rate for Non-Hispanic Black
compared to Non-Hispanic White, Hispanics, and Asian / Pacific Islander; for
age-specific incidence rate, Non-Hispanic Black women will have the highest rate and
Hispanics, Asian and Pacific Islander women will have the lower rates when compared to
Non-Hispanic White women.
Question and Research Hypothesis
b) Are there differences in phenotypic, demographic, and treatment features of
TNBC tumors among races/ethnicities?
There will be significant differences between races/ethnicities for phenotypic,
demographic, and treatment characteristics of TNBC tumors.
Aim of Study
The aim of this study was to determine the TNBC age-adjusted and age-specific
incidence rates among races/ethnicities using Surveillance, Epidemiology, and End
Results (SEER) Program data from the National Cancer Institute. Differences in clinical
and pathologic features of TNBC tumors among races/ethnicities were also assessed. The
SEER Program covers over 28% of the United States (U. S.) population on cancer
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incidence and survival. It collects information from population-based cancer registries
across the U.S. and covers 26% of African American, 38% of Hispanics, and 50% of
Asians (Population Characteristics, n. d.). In this study, 22,908 TNBC cases diagnosed
from 2010 to 2013 were analysed for TNBC incidence rates, and clinico-pathologic
characteristics of TNBC among Non-Hispanic White, Non-Hispanic Black, Hispanic (All
Races), Chinese, Asian Indian, Korean, Vietnamese, and Filipina women.
Methods
This is a cross-sectional retrospective population-based study with secondary data.
Data was included from all 18 SEER cancer registries for identified women diagnosed
with primary invasive breast cancer during the years 2010-2013. The 18 cancer registries
included the Alaska Native Tumor Registry, Atlanta, Connecticut, Detroit, Greater
California, Greater Georgia, Iowa, Kentucky, Louisiana, Los Angeles, New Mexico, New
Jersey, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah.
The SEER population is comparable to the general U. S. population in regards to
poverty and education. The proportion of foreign-born persons is higher among SEER
compared to general U. S. population (Population Characteristics, n. d.). One of the sites
directly linked to SEER cases was the American Community Survey 2010-2014.
SEER*Stat software was used to provide caselisting of the county attributes.
All study related data was obtained from SEER database after signing a Research
Data Agreement for internet data access. SEER*Stat software Version 8.3.2 was used for
data collection and analysis (SEER Statistical Software, n. d.). The SEER Research
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incidence data used for the study was from the November 2015 submission. Exempt
review approval from Clemson University Institutional Review Board was also obtained.
TNBC women with their race/ethnicity recorded as Non-Hispanic White,
Non-Hispanic Black, Hispanic, Chinese, Asian Indian, Korean, Vietnamese, and Filipina,
and age 18 years and older were selected for the study. Chinese, Asian Indian, Korean,
Vietnamese, and Filipina are the fastest growing Asian population in the U.S. and hence
were included in the study (Hoeffel, Rastogi, Kim, & Shahid (2012). The Hispanic
women in this study included Hispanics from all races. For the dependent variable, the
Breast Subtype, “Triple Negative” category was selected. SEER*Stat was used to create a
case listing for primary TNBC female malignant cases aged 18 years and above from the
eight race/ethnic groups in all 18 registries. Other variable information extracted for these
women were age at diagnosis, American Joint Committee on Cancer/AJCC stage, size of
tumor, tumor histology, tumor grade, lymphnode invasion, metastasis, and treatment
(chemotherapy, radiation, surgery).
Data extracted from the SEER database was saved as a raw file in SPSS. Since SEER
gives a unique ID to each case, there were no duplicates. The total number of TNBC case
information extracted for the raw file was 22,909. One case was excluded due to an age
less than 18 years; a total of 22,908 cases were included in the analysis. The median age
at diagnosis was calculated for all TNBC cases. Women who were classified as 85+ years
were coded as 85 and median age was calculated for all TNBC women aged 18 years and
above. Women were grouped into two age categories; less than 40 years and greater than
40 years. Since women less than 40 years of age are not routinely screened for breast
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cancer a cut-off at 40 years was used to categorize. Also, the literature indicates that
women less than 40 years of age will more frequently develop TNBC (Parise & Caggiano,
2017; Sineshaw et al., 2014) .
AJCC Stage was used as coded to assist with data analysis; stages IA and IB were
coded as I, stages IIA, and, IIB as stage II, stages IIIA, IIIB, IIIC, and IIINOS as stage III,
and Stage IV stood alone. There were 52 cases diagnosed at Stage 0 and excluded from
analysis because this stage is a non-invasive cancer and the study’s scope was only
invasive cancers. Tumor Histology was based on the SEER codes including 8500/3:
Infiltrating duct carcinoma, NOS (Non-Specific), 8520/3: Lobular carcinoma,
NOS(Non-Specific), and 8522/3: Infiltrating duct and lobular carcinoma. Tumor
histology outside of these categories were classified as “others.” There were 3,156 TNBC
cases with histology in the “other” classification.
The classification of Tumor Grade included: “Well differentiated; Grade I” coded as
Grade I, “Moderately differentiated; Grade II” as Grade II, “Poorly differentiated; Grade
III” as Grade III and “Undifferentiated; anaplastic; Grade IV” as Grade IV. For tumor
stage and tumor grade, unknown cases were classified as a separate category.
SEER data has tumor size entered in numeric value (millimeters) and some cases
have information as “values under review”, “no primary tumor found, no Paget’s disease”,
“microscopic focus of foci only”, “mammography/xerography diagnosis with no size
given”, “diffuse”, “unknown”, “3 mm or less than 3mm”, “Paget disease of nipple with
no demonstrable tumor.” Median tumor size calculation did not include the
above-mentioned categories because they are not numerical values to include in median
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calculation and the only category included was “3mm or less than 3mm”. The category “3
mm or less than 3mm” was coded as 3mm and was included in median tumor size
calculation.
Lymph node invasion was categorized as yes or no. All cases that had a N1, N2 or
N3 were coded as “yes” and those with N0 as “no.” There were 355 cases with NX
(lymph nodes cannot be evaluated) and 34 cases had NA (Not Applicable); both groups
were excluded from the analysis. Similarly, 34 cases had an NA for Metastasis and were
excluded from analysis. M0 and M0 (i+) were grouped as “no” and M1 as “yes.”
The three variables for treatment are chemotherapy, surgery, and radiation. SEER
does not have hormone therapy information on all data in the November 2015 submission.
Currently SEER is collecting hormone therapy information as part of treatment data for
cancer cases. An additional agreement was signed by the Principal Investigator before
online access was obtained for chemotherapy information on all study cases as the earlier
data did not have chemotherapy information. The database used was Incidence-SEER 18
Regs Custom Data (with chemotherapy recode), Nov 2015 Sub (2000-2013) identical to
Incidence- SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases,
Nov 2015 Sub (2000-2013). A “yes” for chemotherapy indicates that the patient had
chemotherapy as part of first line of treatment and a “no” indicates chemotherapy was not
given or it is unknown (SEER*Stat Technical support, personal communication, August 5,
2016). Note, this can introduce bias when interpreting results and can be a potential threat
to external validity of the study. Noone et al. (2016) reported an overall 68% of
sensitivity for SEER chemotherapy information, but high specificity; if chemotherapy
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information is provided by SEER it was most likely received by the patient (Noone et
al.).
Radiation information in SEER was coded as follows: “beam radiation, combination
of beam with implants or isotopes, radiation, NOS method of source not specified,
radioactive implants, radioisotopes” coded as yes, “none” as no, “recommended,
unknown if administered”, “unknown”, and “refused” as it is.
Surgery was coded as: “surgery performed” as yes, “not recommended,
recommended but not performed, patient refused; recommended but not performed,
unknown reason; not recommended, contraindicated due to other cond; autopsy only
(1973-2002); not performed, patient died prior to recommended surgery” as no, and
“unknown; death certificate; or autopsy only (2003+); recommended, unknown if
performed” as unknown.
Statistical Analyses
The age-adjusted incidence rate was calculated using SEER*Stat software. Age
groups ranging from 20 years and above were selected for incidence rate calculation.
None of the TNBC cases were between 18 and 20 years of age. Rates were obtained for
individual races/ethnicities; Non-Hispanic/NH White, NH Black, Hispanic but not for the
ethnicities of Chinese, Asian Indian, Vietnamese, Korean, and Filipino. This is because
SEER has TNBC case counts but not the population counts for those individual
ethnicities. Hence rates were calculated for Asian and Pacific Islander as one group.
However, when comparing clinico-pathologic characteristics among ethnicities, available
individual ethnicity information was used. All rates were age-adjusted to the U. S.
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Standard Population (19 age-groups-Census P25-1130). The age-groups range in five
years: 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years,
50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years,
and 85+ years.
Statistical software SPSS version 24 was used for comparing TNBC
clinico-pathologic characteristics among the eight groups. Chi-square tests were
employed to compare frequency distributions among the eight ethnic groups for TNBC
clinico-pathologic characteristics including age at diagnosis (less than or greater than 40
years), tumor histology, tumor grade, tumor stage, lymph node invasion, metastasis, and
treatment (chemotherapy, radiation, surgery). Microsoft excel was used to convert the
string values to numerical values (20mm converted 20) and then SPSS was used to
calculate median age at diagnosis and median tumor sizes. A p value of less than or equal
to 0.05 was considered to have statistical significance.
Results
The 18 SEER registries included 22,908 women with a primary breast cancer
diagnosis of TNBC, age > 18 years for the years 2010-2013. TNBC Incidence rates per
100,000 were standardized to the year 2000 United States Standard population (19 age
groups-census P25-1130) and calculated for NH White, NH Black, Hispanic, and Asian
Pacific Islander categories/populations (See Table 3.1). Rates were standardized to the
US Census 2000 general population as it is the most recent census population available
with SEER (Standard Populations, n. d.). NH Black had the highest incidence rate,
516.17 (all rates per 100,000), followed by NH White 287.92 and Hispanics 212.91. The
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lowest incidence rate among the four-major race/ethnicities was 190.60 for the Asian
Pacific Islander category. (See the Methods section for explanation of the collective
incidence rate for the Asian Pacific Islander population instead of five ethnic groups.)
TNBC age-specific rates were calculated for 14 age groups that fell within the
study’s age limit. There were no TNBC cases under age 20 years and the 14 remaining
age groups are 20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49
years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years,
80-84 years, and 85+ years. See Table 3.1 and Figure 3.1 for age-specific rates per
age-group for the major races, rates per 100,000 women standardized to the U. S.
population. Among NH White women ages 70-74 years had the highest age-specific rate
followed by those 65-69 years (35.84 and 33.65 per 100,000 respectively). Among NH
Black women, the 60-64 age group had the highest rate followed by those 65-69 years
(62.43 and 59.41 per 100,000 respectively). For Hispanic women, 65-69 years has the
highest rate followed by those 70-74 years of age (24.81 and 22.54 per 100,000
respectively). Asian / Pacific Islander women was the only group with the highest
age-specific rate for women aged 80-84 years followed by those 65-69 years (20.73 per
100,000).
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Table 3.1
TNBC Age-Specific and Age-adjusted incidence rates for the year 2010-2013
AGE-ADJUSTED AND AGE-SPECIFIC INCIDENCE RATES
Years

NH White

NH Black

Hispanic

NH Asian

Standard

(All Races)

Pacific

Populationa

Islander
20-24

0.17

0.348

0.18

0.164

18,257,225

25-29

1.706

3.383

1.627

1.450

17,722,067

30-34

5.431

8.452

4.299

3.575

19,511,370

35-39

9.5

16.761

9.263

7.182

22,179,956

40-44

15.99

25.762

12.639

10.472

22,479,229

45-49

19.532

37.225

17.338

14.173

19,805,793

50-54

22.793

48.84

19.222

16.287

17,224,359

55-59

25.434

53.451

19.881

16.910

13,307,234

60-64

30.446

62.429

22.539

18.794

10,654,272

65-69

33.648

59.413

24.808

20.971

9,409,940

70-74

35.843

58.247

22.273

20.803

8,725,574

75-79

32.032

59.845

19.538

20.677

7,414,559

80-84

31.209

44.977

21.47

22.084

4,900,234

85+

24.188

37.034

17.837

20.072

4,259,173

Total

287.922

516.167

212.914

193.614

~

~

Unknown

~

~

Note. Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19
age groups - Census P25-1130) standard
Text in bold are the peak age-groups for each race/ethnic group
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Figure 3.1
TNBC Age-Specific Incidence Rate (2010-2013)
70

Incidence Rate (per 100,000 women)

60
50
40
30
20
10
0
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
years years years years years years years years years years years years years years
Non-Hispanic White

Non-Hispanic Black

Hispanic (All Races)

Asian Pacific Islander

Note. Rates are per 100,000 and age-adjusted to the 2000 United States Standard
Population (19 age groups - Census P25-1130)

99

TNBC Phenotypic and Treatment Differences among races/ethnicities
Significant differences were observed among eight groups for TNBC median age at
diagnosis. See Table 3.2. Asian Indian women were the youngest among all eight groups
of TNBC with a median age of 47 years, followed by Hispanic women 52 years of age
and Vietnamese women 55 years of age. The other groups ranged between 56-60 years.
When TNBC women were categorized as less than 40 years and greater than 40 years,
Asian Indian women were the significantly highest proportion followed by Hispanics and
Vietnamese in the less than 40 years’ age-group (30.5%, 19.1% and 17.6% respectively,
p < 0.001). Among TNBC women aged greater than 40 years, NH White women, NH
Black women, and Filipina women were the leading groups (92.4%, 89.5%, and 89.3%
respectively). The differences among races/ethnicities based on age-groups was
statistically significant (p < 0.001). Refer Table 3.3 for demographic characteristics
among women of color.
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Table 3.2
TNBC Phenotypic, Demographic Differences Among Races/Ethnicities.
*p < 0.001, **p = 0.037
*

Non-Hispanic Non-Hispanic Hispanic Chinese Asian Filipina Korean Vietnamese
White
Black
(All
Indian
Races)
60
56
52
56
47
57
56
55
Median age
at
diagnosis,
years
Age Groups
1107
489
531
30
40
38
18
15
<40 years
7.6%
10.5%
19.1%
10.9% 30.5% 10.7%
14.3%
17.6%
Variable

>40 years

13386
92.4%

4169
89.5%

2254
80.9%

246
89.1%

91
69.5%

316
89.3%

108
85.7%

70
82.4%

<40 years:
>40 years

1:12.16

1:8.52

1:4.24

1:8.17

1:2.28

1:8.35

1:5.99

1:4.68

(5513)
38.1%
(5787)
40.0%

(1290)
27.7%
(2029)
43.6%

(756)
27.2%
(1303)
46.9%

(102)
37.0%
(126)
45.7%

(42)
32.3%
(64)
49.2%

(109)
31.0%
(156)
44.3%

(40)
31.7%
(56)
44.4%

(26)
30.6%
(41)
48.2%

III

(2031)
14.0%

(858)
18.5%

(480)
17.3%

(26)
9.4%

(18)
13.8%

(58)
16.5%

(17)
13.5%

(11)
12.9%

IV

(854)
5.9%

(370)
8.0%

(148)
5.3%

(16)
5.8%

(5)
3.8%

(18)
5.1%

(6)
4.8%

(5)
5.9%

Stage At
Diagnosis
I
II
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Table 3.2 continued
Unknown
Stage

(287)
2.0%

(103)
2.2%

(92)
3.3%

(6)
2.2%

(1)
0.8%

(11)
3.1%

(7)
5.6%

(2)
2.4%

Tumor size
(median,
cms)
(N=21527)
Tumor
Histology**
Ductal
Lobular

2.2

2.5

2.5

2.2

2.45

2.4

2.3

2.5

(12057)
96.7%

(3950)
98.0%

(2329)
96.9%

(233)
97.1%

(118)
98.3%

(286)
96.3%

(113)
97.4%

(77)
100.0%

(206)
1.7%

(40)
1.0%

(33)
1.4%

(4)
1.7%

(0)
-

(7)
2.4%

(1)
0.9%

(0)
-

(204)
1.6%

(41)
1.0%

(42)
1.7%

(3)
1.3%

(2)
1.7%

(4)
1.3%

(2)
1.7%

(0)
-

Mixed
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Table 3.3
Demographic Characteristics Among TNBC Women of Color
* p < 0.001
*

Non-Hispanic Non-Hispanic Hispanic Chinese Filipina Vietnamese Korean Asian
White
Black
(All
Indian
Races)
Median Household Income (in tens)
$1915-3999
1140
690
72
1
0
1
0
1
Variable

7.9%

14.8%

2.6%

0.4%

0.0%

1.2%

-

0.8%

$4000-4999

2881

1291

441

2

15

4

3

10

$5000-5999

19.9%
4101

27.7%
1483

15.8%
1294

0.7%
88

4.2%
120

4.7%
22

2.4%
54

7.6%
25

28.3%

31.8%

46.5%

31.9%

33.9%

25.9%

42.9%

19.1%

3035
20.9%
2054
14.2%
714
4.9%

638
13.7%
381
8.2%
119
2.6%

430
15.4%
340
12.2%
98
3.5%

19
6.9%
116
42.0%
7
2.5%

66
18.6%
121
34.2%
7
2.0%

7
8.2%
39
45.9%
0
-

12
9.5%
41
32.5%
12
9.5%

9
6.9%
34
26.0%
19
14.5%

474
3.3%
92

38
0.8%
18

103
3.7%
6

42
15.2%
1

24
6.8%
1

12
14.1%
0

4
3.2%
0

28
21.4%
5

0.6%

0.4%

0.2%

0.4%

0.3%

-

-

3.8%

$6000-6999
$7000-7999
$8000-8999
$9000-9999
$10000-12397
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Table 3.3 (continued)
*

Variable

Insurance
Uninsured

Non-Hispanic Non-Hispanic Hispanic
White
Black
(All Races)

Chinese Filipina

Vietnamese Korean

Asian
Indian

240
1.7%
10781
74.4%
1308

206
4.4%
2695
57.9%
1024

150
5.4%
1479
53.1%
802

5
1.8%
197
71.4%
45

7
2.0%
250
70.6%
56

2
2.4%
38
44.7%
28

5
4.0%
72
57.1%
32

4
3.1%
91
69.5%
15

9.0%

22.0%

28.8%

16.3%

15.8%

32.9%

25.4%

11.5%

1939
13.4%
Unknown
225
1.6%
Persons below poverty Percent

656
14.1%
77
1.7%

312
11.2%
42
1.5%

26
9.4%
3
1.1%

34
9.6%
7
2.0%

15
17.6%
2
2.4%

14
11.1%
3
2.4%

18
13.7%
3
2.3%

279
6.0%
2941
63.1%
1438
30.9%
0

251
9.0%
2118
76.1%
415
14.9%
1

66
23.9%
206
74.6%
4
1.4%
0

83
23.4%
257
72.6%
14
4.0%
0

17
20.0%
65
76.5%
3
3.5%
0

32
25.4%
93
73.8%
1
0.8%
0

55
42.0%
67
51.1%
9
6.9%
0

Insured
Any Medicaid
Insured/No specifics

1.04-9.99%
10-19.99%
20.52-52.63%
Blank

2287
15.8%
9943
68.6%
2261
15.6%
2
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Frequency percentages for TNBC stage at diagnosis among the eight groups were
calculated. Statistically significant differences [X2 (28) = 316.01, p < 0.001] were
observed among race/ethnicities. NH Black women had the highest frequency for Stages
III and IV (18.5% and 8% respectively), Hispanic women had the second highest for
Stage III (17.3%) followed by Filipina women (16.55%). For Stage IV tumors,
Vietnamese women (5.9%) and Chinese women (5.8%) followed NH Black women. For
Stage I tumors, NH White women had the highest frequency (38.1%) and least for
Hispanic women (27.2%) and Asian Indian women had the highest frequency for Stage II
tumors (49.2%). Cases with unknown tumor stage information was categorized as an
independent category and it ranged from 0.8% to 5.6% across eight groups. TNBC tumor
sizes also significantly varied among the eight groups (p < 0.001). The median tumor size
2.5 centimetres (cms) was the same for NH Black, Hispanic, and Vietnamese women.
Asian Indian women had 2.45 cms, Filipina women 2.4 cms, Korean women 2.3 cms, and
Chinese, NH White women had 2.2 cms at the time of diagnosis.
Significant differences were observed for TNBC tumor histology [X2 (14) = 24.75, p
= 0.037]. All groups were similar with the ductal classification as the majority.
Vietnamese women were designated only as ductal carcinoma with no lobular or mixed
carcinoma classifications. There were 98.3% of Asian Indian women identified to have
ductal carcinoma histology followed by NH Black at 98%. For lobular type histology,
frequency ranged from 0% to 2.4% with mixed type ranging from 0% to 1.7%. The
TNBC tumor grade also showed significant differences for different categories among the
eight groups [X2 (28) = 170.43, p < 0.001]. Refer to Table 3.4. Like tumor stage, tumor
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grade also had an ‘unknown’ grade category frequencies per stage that ranged from
2.4-7.2%. Korean women had the highest grade IV frequency (2.4%) while Asian Indian
and Vietnamese women, had no grade IV tumors. However, Asian Indian had the highest
frequency for grade III tumors (84.7%) followed by Vietnamese and NH Black (81.2%
and 79.3%, respectively). For grade II tumors, Chinese women had the highest frequency
followed by Filipina and NH White (23.6%, 21.5%, and 18.5% respectively).
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*

Variable

Tumor Grade
I
II
III
IV
Unknown
Lymph node
involvement
No
Yes
Metastasis
No
Yes

Table 3.4
TNBC Phenotypic Characteristics among Women of Color, *p < 0.001
NH White NH Black Hispanic
Chinese Asian
Filipina
Korean
(All
Indian
Races)

Vietnamese

345
2.4%
2686
18.5%
10585
73.0%
141
1.0%
736
5.1%

70
1.5%
615
13.2%
3694
79.3%
32
0.7%
247
5.3%

45
1.6%
380
13.6%
2171
78.0%
45
1.6%
144
5.2%

6
2.2%
65
23.6%
184
66.7%
1
0.4%
20
7.2%

0
14
10.7%
111
84.7%
0
6
4.6%

10
2.8%
76
21.5%
248
70.1%
6
1.7%
14
4.0%

1
0.8%
19
15.1%
96
76.2%
3
2.4%
7
5.6%

2
2.4%
12
14.1%
69
81.2%
0
2
2.4%

9464
66.4%
4791
33.6%

2655
58.0%
1923
42.0%

1598
58.4%
1137
41.6%

178
65.4%
94
34.6%

77
59.7%
52
40.3%

215
62.3%
130
37.7%

72
60.0%
48
40.0%

56
65.9%
29
34.1%

13621
94.1%

4281
92.0%

2631
94.7%

260
94.2%

125
96.2%

334
94.9%

120
95.2%

80
94.1%

854
5.9%

370
8.0%

148
5.3%

16
5.8%

5
3.8%

18
5.1%

6
4.8%

5
5.9%
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When analysing lymph node involvement and metastasis, significant group
differences were observed among TNBC tumors for lymph node involvement [X2 (7) =
143.99, p < 0.001] and for metastasis [X2 (7) = 32.94, p < 0.001]. The NH Black,
Hispanic (All Races), and Asian Indian groups had the highest frequency for positive
lymph node invasion (42%, 41.6%, and 40.3%, respectively). The NH Black population
had the highest frequency (8%) for metastasis followed by Vietnamese, NH White
women (5.9%), and the lowest incidence among the Asian Indian group (3.8%).
Significant group differences were observed among all three treatment variables:
chemotherapy [X2 (7) = 104.3, p < 0.001]; radiation [X2 (28) = 118.31, p < 0.001]; and
surgery [X2 (14) = 79.321, p < 0.001]. Refer Table 3.5. Among TNBC women, Asian
Indian women had the highest frequency for receiving chemotherapy (85.5%), followed
by Hispanic (75.5%), NH Black (74.5%), Filipina (73.7%), Vietnamese (71.8%), Korean
(70.6%), NH White (68.9%) and 66.3% among Chinese. These results should be
interpreted with caution as SEER collectively provided information about those who did
not receive chemotherapy along with women who had no information on chemotherapy.
The range of unknown cases for radiation was 0-1.1% and 0.7-3.5% for surgery.
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*

Treatment Variable
Chemotherapy
Yes
No/Unknown
Radiation
Yes
No

Recommended, unknown
if administered
Refused
Unknown
Surgery
Yes
No
Unknown

Table 3.5
Treatment Characteristics among Women of Color, *p < 0.001
NH
NH Black Hispanic (All Chinese Asian Filipina Korean
White
Races)
Indian

Vietnamese

9987
68.9%
4506
31.1%

3472
74.5%
1186
25.5%

2103
75.5%
682
24.5%

183
66.3%
93
33.7%

112
85.5%
19
14.5%

261
73.7%
93
26.3%

89
70.6%
37
29.4%

61
71.8%
24
28.2%

6712
46.3%
6875
47.4%
564
3.9%
237
1.6%
105
.7%

2206
47.4%
2100
45.1%
265
5.7%
56
1.2%
31
.7%

1147
41.2%
1441
51.7%
162
5.8%
26
0.9%
9
.3%

121
43.8%
140
50.7%
10
3.6%
4
1.4%
1
.4%

68
51.9%
55
42%
7
5.3%
1
0.8%
0
-

130
36.7%
193
54.5%
22
6.2%
5
1.4%
4
1.1%

45
35.7%
71
56.3%
9
7.1%
1
.8%

31
36.5%
46
54.1%
5
5.9%
3
3.5%
0
-

13256
91.5%
1095
7.6%
142
1.0%

4094
87.9%
475
10.2%
89
1.9%

2488
89.3%
254
9.1%
43
1.5%

251
90.9%
23
8.3%
2
0.7%

125
95.4%
4
3.1%
2
1.5%

322
91.0%
25
7.1%
7
2.0%

110
87.3%
12
9.5%
4
3.2%

77
90.6%
5
5.9%
3
3.5%
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For cases that received radiation, Asian Indian women had the highest frequency
followed by NH Black and NH White women (51.9%, 47.4%, and 46.3%, respectively).
Chinese women had a frequency of 43.8%, Hispanic 41.2%, Filipina 36.7%, Vietnamese
36.5% and Korean 35.7%. For no radiation, the leading groups were Korean (56.3%),
Filipina (54.5%), and Vietnamese (54.1%). The remaining groups had the following
percentages: Hispanic (All Races), 51.7%; Chinese, 50.7%; NH White, 47.4%; NH Black,
45.1% and Asian Indian, 42%. All eight groups included cases who were recommended
to have radiation therapy (RT), but the information was unknown if they received the RT
or not. This percentage was highest for Korean (7.1%) and least for Chinese (3.6%). The
percentage of women who refused to have RT was highest for the Vietnamese (3.5%) and
lowest for the Korean women with no cases recorded.
Among eight groups, 95.4% of Asian Indian women underwent surgery and the other
groups ranged between 87.3%-91.5%. NH Black women had the highest percentage for
not having a surgery (10.2%), followed by Korean (9.5%) and Hispanic women (9.1%).
The other five groups not receiving surgery ranged from 3.1% to 8.3%.
Missing cases were grouped as an individual category and were included only for
frequency calculation. No data was transformed. Missing data ranged from 0.8% to 5.6%,
assumed to be missing at random and due to the lower percentage of missing data,
statistical imputation of values was not performed.
Discussion
Our study is the most recent using a TNBC sample collected from 18 SEER
Registries for the years 2010 to 2013. The sample included women from three major
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races/ethnicities (NH White, NH Black, and Hispanic) and five ethnicities (Chinese,
Asian Indian, Filipina, Vietnamese, and Korean). We reported age-adjusted and
age-specific incidence rates on NH White, NH Black, Hispanic, and NH Asian Pacific
Islander. The most recent information in published literature is from cases diagnosed in
the year 2010 and reported by Howlader et al. (2014). Another study used cases
diagnosed between 2006 and 2009. The findings of this study are consistent with
Howlader et al.’ overall ranking of age-adjusted incidence rates (NH Black women with
the highest, followed by NH White, Hispanics and NH Asian Pacific Islander women)
(Clarke et al., 2012). However, our study differed in that NH Black women had their peak
TNBC age-specific incidence rate at a younger age in the age-group 60-64 years followed
by 65-69 years. Howlader et al. (2014) study reported the peak rate for age-group 65-69
years old.
For TNBC age-specific incidence rates, our study found NH Black group highest for
all 14 age-groups with NH White, Hispanic and NH Asian Pacific Islander groups having
variable ranking after NH Black. See Table 3.1. Also, there were differences among the
age-groups where TNBC peaked for each major racial group. Other published studies
with reported TNBC incidence rates reported only on NH White, NH Black, and Hispanic
women (Kohler et al., 2015, Plasilova et al., 2016, Amirikia, Bills, Bush & Newman,
2011). This study results agree with these published studies that NH Black women have
highest incidence, almost double that of NH White or the Hispanic women and the least
incidence observed were among the NH Asian Pacific Islander women. Two published
studies reported on age-adjusted rates were limited by sampling: age restricted to 50-79
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years (Phipps et al., 2011), ethnicity restricted to White and Black (Lund et al., 2009).
The disproportionate burden of TNBC among NH Black warrants further research on risk
factors including, but not limited to genetic mutations, family history, nativity status, age,
income, education, insurance, reproductive factors (menarche, menopause, parity, breast
feeding, oral contraceptive pill usage), lifestyle (exercise, smoking, alcohol) and others.
In this research study TNBC was found to present as ductal carcinoma,
consistent with previously published studies (Kanaan et al., 2014; Llanos et al., 2015;
Orucevic et al., 2015; Plasilova et al., 2016; Swede et al., 2011; Tawfik et al., 2010; Telli
et al., 2011), and less likely to be lobular or mixed type (Rummel, Varner, Shriver, &
Ellsworth, 2013; Swede et al., 2011; Tawfik et al., 2010). Also, our study noted, 60-70%
of the TNBC cases were Stage II and above with the highest percentage among NH
Blacks, lowest among NH White and other ethnic groups in-between, consistent with the
published literature (Parise & Caggiano, 2017; Llanos et al.2015; Rummel, Varner,
Shriver, & Ellsworth, 2013; Brown, Tsodikov, Bauer, Parise, & Caggiano, 2008; Lin et
al., 2012; Bauer et al., 2007). Our study further affirms previous findings that TNBC
median tumor size at presentation is significantly greater than 2cms (Santebennur,
Palanisamy, Gabriel, & Sanmugarajah, 2008; Parise & Caggiano, 2017; Banegas et al.,
2014; Sineshaw et al., 2014; Plasilova et al., 2016; Llanos et al., 2015; Kanaan et al.,
2014). The incidence of TNBC grade III tumors in our study, 67.1 % to 84.7 %, was also
found to be similar to that found in other studies like previously published in literature
(Plasilova et al.2016; Parise & Caggiano, 2017; Sineshaw et al, 2014; Llanos et al., 2015;
Banegas et al., 2014; Tawfik et al, 2010; Orucevic et al., 2015; Kanaan et al., 2014;
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Rummel et al., 2013; Zaky et al., 2011). Our study reports findings on metastasis
consistent with Zaky et al. that NH Black women have the highest frequency. For
positive lymphovascular invasion among TNBC cases, our study provides statistical
significant (p < 0.001) information for eight race/ethnicities. Studies had previously
reported on only Hispanic women (Banegas et al., 2014), or African American and
Caucasian women (Tawfik et al., 2010) and only non-significant (p = 0.856) differences
among African American and Caucasian TNBC women (Sturtz et al., 2014).
Significant phenotypic differences among the eight groups were observed in our
study. Our study provides further evidence of the association between TNBC and median
age at diagnosis. Consistent with previous findings, NH Black women were found to be
diagnosed at a younger age compared to other ethnic groups (Sullivan et al., 2014). Our
study is the first to report statistically significant differences between ethnic groups for
TNBC stage, tumor grade, tumor histology, tumor size, lymph node involvement,
metastasis, and treatment (for all p < 0.001, except histology, p = 0.037).
Non-significant ethnic differences have been reported by (Sullivan et al., 2014;
Pacheco et al., 2013; Chu, Henderson, Ampil & Li, 2012; Dawood et al. 2009; Iqbal et al.
2015; Sturtz et al., 2014). Smaller sample sizes (Chu, Henderson, Ampil & Li, 2012;
Sturtz et al., 2014), sampling restricted to one type of patient treatment (Dawood et al.,
2009), or early stages of cancer (Chu et al., 2012), smaller tumor sizes (Iqbal et al., 2015),
or an individual clinic sample (Pacheco et al., 2013) could be reasons for the
non-significance findings in these studies. Studies that examined TNBC phenotypic
differences among ethnicities focused predominantly on African American and Caucasian
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women. Our study is the first study to analyze five individual Asian sub-groups as well as
Hispanic women in addition to the major races, NH Black and NH White.
This study is the first to provide the TNBC incidence rates on major races in the
U. S. for the most recent years (2010-2013) and to illustrate the TNBC phenotypic
differences among ethnicities. Still one of the limitations of our study is the lack of
population count for the five Asian origin ethnicities: Chinese, Asian Indian, Filipina,
Korean and Vietnamese, to calculate the respective incidence rates. This lack of
information prevents us from identifying the TNBC burden among those women. Of note,
SEER does have pertinent information on clinical and pathological data for all TNBC
cases which allowed us to highlight the racial/ethnic differences for TNBC risk. Another
limitation is the lack of detailed information on chemotherapy and hormone therapy on
all cases. Currently SEER is undertaking efforts to provide more information on
chemotherapy details of patient.
Limitations encountered in this study included the lack of population count for the
five Asian ethnicities. A second limitation was the incomplete information in the SEER
registry on hormone therapy, chemotherapy and a lack of information on nativity status.
SEER is currently undertaking efforts to provide information on these variables.
In summary, TNBC clinically presents as a tumor with larger diameters,
predominantly as ductal carcinoma, higher grade, later stage at presentation, and in
younger age groups of NH White, NH Black, Hispanic, Chinese, Asian Indian, Filipina,
Korean and Vietnamese women. Significant ethnic differences were noted for the TNBC
phenotype and NH Black women along with the few Asian sub-groups, to have higher
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TNBC burden compared to NH White women. Additional research examining the risk
factors in association with TNBC and TNBC phenotype differences among diverse
sample population is needed to confirm our study findings and to enhance measures to
decrease the TNBC impact on the lives of these women.
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CHAPTER 4
RISK FACTORS ASSOCIATED WITH THE TRIPLE-NEGATIVE BREAST
CANCER SUBTYPE AMONG EIGHT RACE/ETHNIC GROUPS AND MODEL
PREDICTION
Introduction
Breast cancer (BC) is one of the common cancer types diagnosed in women with
a high frequency in the United States (U.S.). The American Cancer Society (2017)
estimated 252,710 new female breast cancer cases with an estimated 40,610 deaths for
the year 2017 (Cancer Facts and Figures, 2017). The overall breast cancer incidence rate
(2009-2013) remains as 123.3 (per 100,000 age adjusted to the 2000 U. S. standard
population) reported by North American Association of Central Cancer Registries (Siegel,
Miller, & Jemal, 2017).
Although the death rate has declined since 2000 and reached its lowest level for
the years 2010-2014 as 21.2 (per 100,000 age adjusted to 2000 U. S. standard population),
the death rates vary between race/ethnicities and BC subtypes. Non-Hispanic Black
women lead with a death rate of 30 followed by Non-Hispanic White women (21.1),
Hispanic women (14.4) and least among Asian and Pacific Islander women (11.3), all
rates per 100,000 age adjusted to 2000 U.S. standard population (Mortality Statistics,
2010-2014). Intrinsic breast cancer subtypes from the St. Gallen 2011 Consensus has four
subtypes: Luminal A, Luminal B, Erb-B2 overexpression, and Basal-like (surrogate
definition is Triple Negative Breast Cancer [TNBC]). Women with TNBC were twice as
likely to die from the disease compared to all other BC subtypes (p < 0.0001) (Matt,
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Mozayen, Gress, & Tirona, 2015). Even among TNBC cases, African American women
with Stage III TNBC had a higher risk of breast cancer death compared to White women
(n=103,498), even after adjusting for tumor characteristics, first course of treatment,
neighborhood socio economic status and insurance status (Tao, Gomez, Keegan, Kurian,
& Clarke, 2015). Hispanic women with TNBC data recorded in the California Cancer
Registry was used by Banegas et al. (2014) to report a poorer survival compared to
HR+/HER2- tumors.
The breast cancer sub-types Luminal A, Luminal B, and Erb-B2 overexpression
can be grouped as Non-TNBC cases and compared with TNBC (basal-like). TNBC
patients compared to Non-TNBC patients had 50% increased risk for all-cause mortality
and even after covariate adjustment TNBC was associated with non-Breast Cancer
mortality such as circulatory system diseases, other cancers or causes (HR = 2.15) and
Breast Cancer-mortality (HR = 1.42) (Lian et al., 2014). Studies on ethnic differences in
TNBC cases predominantly concentrated on White, Black, Hispanic women population,
and Asians grouped as Asian Pacific Islander (Parise and Caggiano, 2017; Plasilova et al.,
2016; Sineshaw et al., 2014). Also, studies were primarily single institution or single
registry studies (Parise and Caggiano, 2017; Llanos et al., 2015; Sullivan et al., 2014;
Sturtz et al., 2014; Banegas et al., 2014; Pacheco et al., 2013; Tawfik et al., 2010; Chu et al.,
2012; Swede et al., 2011).
Purpose of the Study
The research question and hypotheses related to the problem of interest are:
Question and Research hypothesis
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a) What are the variables that are associated with TNBC compared to non-TNBC
among the eight groups?
Race/ethnicity, age at diagnosis, tumor histology, tumor size, tumor grade, tumor stage,
lymph node invasion, metastasis, and treatment (radiation, surgery, chemotherapy) will
be associated with TNBC.
Question and Research hypothesis
b) Will there be higher/lesser odds for any race/ethnic group to develop TNBC
compared to Non-Hispanic White women?
Non-Hispanic Black, Hispanic (All Races), Korean, Asian Indian women will have
significantly higher odds for TNBC compared to Non-Hispanic White women and Chinese,
Filipina, Vietnamese women will have lower odds compared to Non-Hispanic White
women.
Question and Research Hypothesis
c) What are the predictors for TNBC compared to Non-TNBC among the eight ethnic
groups?
Race/ethnicity, age at diagnosis, tumor grade and tumor stage will significantly predict
the risk for developing TNBC among the eight races/ethnicities.
Hence the purpose of the study was to identify potential predictive factors (age at
diagnosis, race/ethnicity, education, income, SES, insurance status, nativity) for TNBC
among women of color using a large sample database. Also, to assess the odds for
race/ethnic groups (Non-Hispanic Black, Non-Hispanic White, Hispanics, Asian Indian,
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Chinese, Filipina, Vietnamese, and Korean women) to develop TNBC compared to
Non-Hispanic White women.
Methods
Data from the 18 SEER cancer registries was used to identify women diagnosed with
primary invasive breast cancer during the years 2010-2013. The 18 cancer registries
included in the study serve Alaska Native Tumor Registry, Atlanta, Connecticut, Detroit,
Hawaii, Iowa, Greater California, Rural Georgia, Greater Georgia, Kentucky, Louisiana,
Los Angeles, New Mexico, New Jersey, San Francisco-Oakland, San Jose-Monterey,
Seattle-Puget Sound, and Utah. The SEER population is comparable to the general
United States (U. S.) population in regards to poverty and education. The proportion of
foreign-born persons is higher among SEER compared to the general U. S. population
(Population Characteristics, 2017). Although SEER does not indicate rationale for the
higher levels of foreign-born population when compared to the U. S. general population,
it is possible that this may be due to the higher frequency of Asian immigrants in those
areas covered by SEER Registries. All study related data was obtained from SEER
database after signing a Research Data Agreement for internet data access. SEER*Stat
software Version 8.3.2 was used for data collection and analysis
(www.seer.cancer.gov/seerstat). The SEER Research data used for the study was from
November 2015 submission. Exempt review approval from Clemson University
Institutional Review Board was obtained.
From the SEER database, all women age 18 years and older with their self-identified
race/ethnicity recorded as Non-Hispanic White, Non-Hispanic Black, Hispanic, Chinese,
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Asian Indian, Korean, Vietnamese, and Filipina, were selected for the study. The
Hispanic women in this study includes Hispanics from all races. For the variable, Breast
Subtype (2010+), ‘Triple Negative’ category was selected for the TNBC group and breast
cancer subtypes ‘Her2+/HR+’, ‘Her2+/HR-’, ‘Her2-/HR+’ were collectively grouped as
Non-TNBC women. The above-mentioned BC subtypes as noted by SEER are noted
elsewhere as HR+/Her2+, HR+/Her2-, HR-/Her2+. The investigators used SEER*Stat to
create a case listing for primary TNBC and Non-TNBC female malignant cases from all
18 registries. Other variable information that were extracted included: race/ethnicity, age
at diagnosis, insurance, median household income (in tens) from the American
Community Survey (ACS) 2010-2014, the American Joint Committee on Cancer/AJCC
for stage, size of tumor, tumor histology, tumor grade, lymph node involvement,
metastasis, and treatment (chemotherapy, radiation, surgery). For median household
income level, SEER reports the dollars in number values which needs to be multiplied by
10 to get the original income in dollars.
Data extracted from SEER database was saved as a raw file in SPSS. Total TNBC
case information that was extracted for the raw file was 22,909. Similarly, for
Non-TNBC, the raw file extracted 171,733 cases. After exclusion of two cases due to age
less than 18 years, one in each group, 22,908 cases from TNBC and 171,732 from
Non-TNBC (total sample number of 194,640 women) were included in data analysis.
Median age at diagnosis was calculated for both groups. Women who were classified as
85+ years were coded as 85 (using Microsoft excel) and median age was calculated for
study sample using SPSS. Women were grouped into two age categories: less than 40
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years and more than 40 years and included in analysis. Forty years was used as a cut-off
for age group categories as breast cancer screening for women start at the age of forty.
SEER provides information on insurance status of the women at the time of diagnosis.
They are entered as “uninsured, any Medicaid, insured, insured/no specifics, insurance
status unknown.”
SEER also provides county attributes that were taken from American Community
Survey 2010-2014. They include Median household income in the past 12 months (in
2015 inflation-adjusted dollars) and the percent of persons whose income were below
poverty level of the U. S. in the past 12 months. The American Community Survey
County attributes were obtained along with other variable information. SEER database
already has the information on median household income and persons below poverty
percent directly linked to each SEER case. Median household income is provided in tens
ranging from $1915 to $12397. Percent of persons below poverty is provided in a range
from 1.04% to 52.63%. The above two variables were categorized into different levels for
the given range. Those cases with less than 10% for poverty percent were categorized as
high Socio Economic Status (SES), 10-19.9% for medium SES and greater than 20% for
low SES. Using the county attribute of “percentage of persons living below the US
poverty line” has proven to be the best measure to assess SES (Krieger et al., 2002).
The AJCC Stage was coded for data analysis as: stages IA and IB coded as I, stages
IIA, IIB as stage II, stages IIIA, IIIB, IIIC, IIINOS as stage III, and Stage IV remained
the same. There were 52 cases at Stage 0 and were excluded from analysis. For other
variables: 1) Tumor Histology: SEER codes used- 8500/3: Infiltrating duct carcinoma,
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NOS, 8520/3: Lobular carcinoma, NOS, 8522/3: Infiltrating duct and lobular carcinoma
and the rest were categorized as “others.” There were 3,156 TNBC cases with histology
of “other” categories and these were excluded from analysis. Tumor Grade: “Well
differentiated; Grade I” coded as Grade I, “Moderately differentiated; Grade II” as Grade
II, “Poorly differentiated; Grade III” as Grade III and “Undifferentiated; anaplastic;
Grade IV” as Grade IV. Unknown cases were classified as a separate category in tumor
stage and tumor grade.
SEER has tumor size entered in numeric value (millimetres) and some cases has
information as “values under review”, “no primary tumor found, no Paget’s disease”,
“microscopic focus of foci only”, “mammography/xerography diagnosis with no size
given”, “diffuse”, “unknown”, “3 mm or less than 3mm”, “Paget disease of nipple with
no demonstrable tumor.” Median tumor size was calculated for the eight race/ethnic
groups. The only category other than direct numerical values that was included in
calculation was “3 mm or less than 3mm” and it was coded as <3mm. All other
categories mentioned above were not included in median tumor size calculation.
Microsoft excel was used to convert the string values to numerical values (example:
20mm converted 20) and then SPSS was used to calculate median tumor sizes. Lymph
node involvement was categorized as yes and no. All cases that had a N1, N1a, N1b, N1c,
N1mi, N1NOS, N2, N2a, N2b, N2NOS or N3, N3a, N3b, N3c, N3NOS was coded as
“yes” and those with N0, N0(i-), N0(i+), N0(mol-), N0(mol+) was a “no.” 2716 cases had
a NX (lymph nodes cannot be evaluated) and were excluded from the analysis, but not
the 39 cases with NA (Not Applicable) which was categorized separately. Similarly, there
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were 39 cases that had an NA for metastasis and they were excluded from regression
analysis. M0 and M0 (i+) were grouped as “no” and M1 as “yes.”
The three variables under treatment are Chemotherapy, Surgery, and Radiation.
SEER does not have hormone therapy information on all data in the November 2015
submission. SEER is currently collecting hormone therapy information as part of
treatment data for cancer cases. An additional agreement was signed before access was
obtained for chemotherapy information on all study cases. The rationale is discussed
under study limitations. The database we used was Incidence-SEER 18 Regs Custom
Data (with chemotherapy recode), Nov 2015 Sub (2000-2013) identical to IncidenceSEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015
Sub (2000-2013). “Yes” for chemotherapy indicates that patient had chemotherapy as
part of first line of treatment and “no” indicates chemotherapy not given or unknown
(SEER*Stat Technical support, personal communication, August 5 2016). Noone et al.
(2016) reported an overall 68% of sensitivity for SEER chemotherapy information, but
high specificity which means that if chemotherapy information is given in SEER then it
was most likely received by the patient.
Radiation information in SEER was coded into five categories: a) beam radiation,
combination of beam with implants or isotopes, radiation, NOS method of source not
specified, radioactive implants, radioisotopes (coded as “yes’), b) none (“no”), c)
recommended, unknown if administered, d) unknown, and e) refused. Surgery coded into
four categories as follows: a) surgery performed as “yes”, b)recommended but not
performed, patient refused/ recommended but not performed, unknown reason as
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“refused”, c) not recommended, contraindicated due to other cond; autopsy only
(1973-2002)/ not performed, patient died prior to recommended surgery/ not
recommended as “no”, and d) unknown; death certificate; or autopsy only (2003+)/
recommended, unknown if performed as “unknown.” Missing cases were categorized as
an individual level and was included only for frequency calculation (see Table 4.3 and
Table 4.4) Missing cases at random were excluded from regression analysis. No data was
transformed.
Statistical Analyses
Statistical software SPSS version 24 was used for comparing TNBC and Non-TNBC
clinico-pathologic characteristics. Chi-square tests were employed to compare frequency
distributions between the two groups for clinico-pathologic characteristics: age at
diagnosis (<40> years), race/ethnicity, tumor histology, tumor grade, tumor stage, lymph
node involvement, metastasis, and treatment (chemotherapy, radiation, surgery). A
Binary Logistic Regression model was used to calculate beta coefficients, Odds Ratios
(ORs) and 95% confidence intervals to quantify associations between various predictors
and TNBC/non-TNBC group. For model prediction, the total sample number was
160,423 including TNBC and non-TNBC cases, which is after excluding cases
categorized as “Others” for histology (20,363), unknown tumor stage and stage 0 (3,382),
unknown tumor grade (6,328), unknown insurance status (2,257), unknown radiation
(777), missing poverty percent (18 women with the same cases missing median
household income information as well), and unknown information for surgery (1,092).
Four models were constructed for predicting TNBC group membership using statistically
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significant variables. Model 1 was an unadjusted model for TNBC/non-TNBC and
race/ethnicity. Model 2 adjusted for all predictors and included race/ethnicity, age groups
(less than and greater than 40 years), insurance status, median Household income, percent
below poverty, tumor histology, tumor grade, tumor stage, surgery, and radiation. Tumor
size, lymph node involvement, and metastasis was not included as they are part of tumor
stage variable information. Model 3 was again an adjusted model with only variables that
contributed significantly to the model. Model 4 was an adjusted model with interaction
effects between predictor variables. P value of less than equal to 0.05 was considered
statistically significant.
Results
For the years 2010-2013, the 18 SEER registries had data on 171,732 Non-TNBC
cases and 22,908 women whose primary breast cancer diagnosis was TNBC, aged 18
years and above. TNBC proportions among Non-Hispanic White, Non-Hispanic Black,
Hispanic, Chinese, Asian Indian, Korean, Vietnamese, and Filipina women were
calculated. Among all cases (TNBC and Non-TNBC cases), NH Black had the highest
frequency (21.25%) for TNBC followed by Asian Indian (12.96%), Hispanic (12.69%),
Korean (12.1%), NH White (10.3%), Chinese (9.38%), Vietnamese (9.1%), and Filipino
(8.44%). See Figure 4.1.
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Figure 4.1
Percentage of TNBC among all Breast Cancer
cases (2010-2013)
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Statistically significant [X2 (7) = 2276, p < 0.001] differences were observed for
frequency of the eight races/ethnicities between the TNBC and non-TNBC groups.
Compared to non-TNBC group, the proportion of NH White, Chinese, and Vietnamese
women was less in TNBC. However, for NH Blacks the frequency for TNBC women was
twice that of Non-TNBC (20.3% versus 10% respectively). Similarly, Hispanic, Filipino,
Asian Indian and Korean women had greater frequency of TNBC than non-TNBC.
Median age at diagnosis was calculated for TNBC and non-TNBC groups. See Table
4.1. Statistical significance (p < .001) was obtained for the differences in median age at
diagnosis which was 62 years among non-TNBC and 58 years among TNBC women. For
women, less than 40 years of age, statistically significant higher frequency observed for
TNBC group when compared to non-TNBC group (p < .001; 9.9% versus 5.4%
respectively).
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Table 4.1
Comparison of Demographic Characteristics between TNBC
and non-TNBC Cases, *p < 0.001
Variable*

Median age at
diagnosis, years
Age groups
< 40 years
> 40 years
Race/Ethnicity
(N=194,640)
Non-Hispanic
White
Non-Hispanic
Black
Hispanic (All
Races)
Chinese
Filipino
Vietnamese
Asian Indian
Korean

Non-TNBC
Count
%
62

TNBC Count
%

9325
5.4%
162407
94.6%

2268
9.9%
20640
90.1%

126158
73.5%
17258
10.0%
19165
11.2%
2665
1.6%
3842
2.2%
849
0.5%
880
0.5%
915
0.5%

14493
63.3%
4658
20.3%
2785
12.2%
276
1.2%
354
1.5%
85
0.4%
131
0.6%
126
0.6%
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Table 4.1 continued
Variable*
Persons below poverty
Percent (n=194,640)
1.04-9.99%
10-19.99%
20-52.63%
Blank
Insurance Status
(n=194,640)
Uninsured
Insured
Any Medicaid
Insured/No specifics
Insurance status unknown
Median Household
Income (in tens) (N=194,595)
1915-3999
4000-4999
5000-5999
6000-6999
7000-7999
8000-8999
9000-9999
10000-12397

Non-TNBC Count
%

TNBC Count %

27317
15.9%
120018
69.9%
24355
14.2%
42
-

3070
13.4%
15690
68.5%
4145
18.1%
3
-

3047
1.8%
124011
72.2%
18726
10.9%
22982
13.4%
2966
1.7%

619
2.7%
15603
68.1%
3310
14.4%
3014
13.2%
362
1.6%

10729
6.2%
30135
17.6%
52487
30.6%
34265
20.0%
26868
15.6%
8892
5.2%
7115
4.1%
1199
0.7%

1905
8.3%
4647
20.3%
7187
31.4%
4216
18.4%
3126
13.6%
976
4.3%
725
3.2%
123
0.5%
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Statistically significant differences [X2 (4) = 367.42, p < 0.001] exist for insurance
status at the time of diagnosis between the two groups. Percentage of women in uninsured
category is higher for TNBC group compared to non-TNBC (p < .001; 2.7% versus 1.8%
respectively). Presence of any Medicaid at the time of diagnosis was in higher
proportions for TNBC compared to non-TNBC group. Percentage of women insured was
higher for non-TNBC group compared to TNBC group (72.2% versus 68.1%).
Statistically significant differences were observed between TNBC and non-TNBC
groups when assessed for county attribute variables such as persons below poverty
percent, an attribute found in the American Community Survey. Statistical significant [X2
(3) = 299.3, p < 0.001] differences exist between the two groups for persons below
poverty percent. Among breast cancer women who belong to 20-56.3% below poverty
percent (low SES), higher frequency observed for TNBC versus non-TNBC group (18.1%
versus 14.2% respectively) For levels less than 9.99% (high SES) and 10-19.99%
(medium SES), TNBC group ranked lesser in frequency compared to Non-TNBC group.
Median household income which is another county attribute showed significant [X2 (7) =
388.54, p < 0.001] differences between groups. Higher proportions observed for TNBC
for levels from $1915 to $5999 (in tens) and lower proportions from $6000 to 12397 (in
tens) when compared to non-TNBC group.
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Table 4.2
Comparison of Phenotypic Characteristics between TNBC and non-TNBC
*p < 0.001
Variable*
Stage At Diagnosis
I
II
III
IV
NA
Unknown Stage
Tumor size
(median, cms)
<2cms
2-5cms
>5 cms
Unknown
Tumor Histology
Ductal
Lobular
Mixed
Tumor Grade
I
II
III

Non-TNBC
%

TNBC
%

87292
50.8%
53696
31.3%
18739
10.9%
8517
5.0%
5
0.0%
3435
2.0%
1.70

7878
34.4%
9562
41.7%
3499
15.3%
1422
6.2%
34
0.1%
509
2.2%
2.0

90471
54.7%
55704
33.7%
13961
8.4%
5269
3.2%
126213
81.7%
17695
11.5%
10617
6.9%
41574
24.2%
77448
45.1%
43984
25.6%

12627
47.7%
10081
38.0%
2972
11.2%
816
3.1%
19163
97.0%
291
1.5%
298
1.5%
479
2.1%
3867
16.9%
17158
74.9%
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Table 4.2 continued
IV
Unknown
Lymph node
involvement
No
Yes
Not Applicable

502
0.3%
8224
4.8%

228
1.0%
1176
5.1%

114320
67.5%
55046
32.5%
5
-

14315
63.5%
8204
36.4%
34
0.2%

Metastasis
No
Yes

163210
95.0%
8517
5.0%
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21452
93.8%
1422
6.2%

Statistically significant (p < 0.05) differences were observed between TNBC and
Non-TNBC groups when clinico-pathologic characteristics were assessed (refer Table
4.2). For stage of cancer [X2 (5) = 2416.1, p < 0.001], approximately two-thirds of TNBC
cases were frequently observed in stages II and above compared to only 50% among
non-TNBC cases. For stages III and IV, 15.3% and 6.2% were TNBC cases compared to
10.9 % and 5.0% among non-TNBC cases. Tumor sizes were categorized as < 2cms,
2-5cms and >5cms with 49.2% of TNBC cases found to be 2cms and above compared to
42.1% among Non-TNBC cases. TNBC median tumor size was found to be statistically
significantly [X2 (3) = 538.22, p < 0.001] larger than non-TNBC tumors (2 cms versus 1.7
cms respectively). Statistically significant differences were observed between TNBC and
non-TNBC groups for tumor histology [X2 (2) = 2987.52, p < 0.001]. Almost all TNBC
cases were infiltrating ductal carcinoma (97%) compared to 81.7% among non-TNBC
cases. For tumor histology, as mixed type (infiltrating ductal and lobular carcinoma), 6.9%
cases among Non-TNBC cases compared to only 1.5% among TNBC cases. Similarly,
high proportions of non-TNBC cases were observed to be lobular carcinoma compared to
1.5% among TNBC cases.
Statistically significant differences were observed between TNBC and non-TNBC
groups for tumor grade [X2 (4) = 24330.39, p < 0.001], lymph node involvement [X2 (2) =
352.8, p < 0.001] and metastasis [X2 (1) = 65.81, p < 0.001]. Approximately 75.9% of
TNBC cases were observed to be tumor grades III and above compared to only 25.9% of
cases among non-TNBC cases. Many non-TNBC cases were Grade II, moderately
differentiated (45.1%) whereas most TNBC cases (74.9%) were Grade III, poorly
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differentiated. For lymph node involvement, 36.4% of TNBC cases versus 32.5% of
non-TNBC were positive. Similarly, a higher percentage of TNBC cases had positive
metastasis compared to non-TNBC cases (6.2% versus 5% respectively). There also were
statistically significant differences noted for treatment variables such as surgery [X2 (3) =
95.42, p < 0.001], chemotherapy [X2 (1) = 9903.38, p < 0.001], and radiation [X2 (4) =
177.79, p < 0.001] between TNBC and Non-TNBC groups. For surgical treatment,
slightly higher proportions were observed among Non-TNBC cases (91.9% versus 90.5%
among TNBC cases). Almost twice the number of TNBC cases received chemotherapy
compared to Non-TNBC cases (71% versus 36.6% respectively) and higher percentage of
Non-TNBC cases compared to TNBC cases did not receive chemotherapy or
chemotherapy information is unknown (63.4% versus 29% respectively). For treatment
(refer to Table 4.3), 49.4% of Non-TNBC cases and 45.7% of TNBC cases received
radiation; 1.8% of Non-TNBC cases and 1.5% of TNBC cases refused radiation treatment.
Tumor stage, size, grade had unknown cases and lymph node invasion status included
‘not applicable’ cases and their frequency for each group can be seen in Table 4.2.
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Table 4.3
Treatment Characteristics, TNBC vs non-TNBC
*p < 0.001
Variable*

Non-TNBC Count
%

TNBC Count
%

157900
91.9%
10671
6.2%
1775
1.0%
1386
0.8%

20723
90.5%
1674
7.3%
219
1.0%
292
1.3%

No/Unknown

108828
63.4%

6640
29.0%

Yes

62904
36.6%

16268
71.0%

84791
49.4%
76836
44.7%
5933
3.5%

10460
45.7%
10921
47.7%
1044
4.6%

3079
1.8%
1093
0.6%

332
1.4%
151
0.7%

Treatment
Surgery
Yes
No
Refused
Unknown
Chemotherapy

Radiation
Yes
No
Recommended,
unknown if
administered
Refused
Unknown
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Only the significant (p < 0.05) results from the logistic regression are summarized
in Table 4.4. Non-TNBC was the reference outcome and NH White women was the
reference race category. NH Black women followed by Hispanic women were
significantly more likely to be diagnosed with TNBC (NH Blacks: OR = 2.42, 95% C.I. =
1.63-3.59; Hispanics: OR = 1.72, 95% C.I.=1.12-2.66). Non-significant higher odds were
observed for the TNBC group of Filipino (p = 0.40) and Vietnamese women (p = 0.36)
and non-significant lower odds for Chinese (p = 0.38), Korean (p = 0.83) and Asian
Indian women (p = 0.99). Women older than 40 years of age were found to have
significant (p < 0.001) lesser odds (OR = 0.91, 95% C.I.=0.84-0.98) of developing TNBC
compared to women less than 40 years of age. Women whose median household income
is less than $5000 (in tens) were at significantly (p = 0.001) higher odds for TNBC
compared to women income more than $5000 (in tens) (OR = 0.93, 95% C.I.=0.88-0.97)
and compared to insured women, uninsured women are significantly (p = 0.01) more
likely to be in TNBC group (OR = 1.16, 95% C.I.=1.04-1.30).
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Table 4.4
Significant Predictors for TNBC Risk with OR (95% C. I.)
Variable

B

Wald
Statistic

P value

Exp (B) with
95% C.I.

Non-Hispanic

0.884

19.369

0.000

2.419 (1.632-3.586)

Hispanic

0.544

6.028

0.014

1.722 (1.116-2.658)

Age

-0.099

6.063

0.014

0.906 (.838-.980)

-0.183

5.694

0.017

0.833 (.716-.968)

-0.523

3.892

0.049

0.593 (.353-.997)

NH Black

0.884

19.369

<.00001

2.419 (1.632-3.586)

Median

-0.078

10.298

0.001

0.925(.882-.970)

-1.484

355.829

<.00001

0.227 (.194-.265)

-1.269

285.372

<.00001

0.281 (.243-.326)

Insurance (none)

0.150

6.550

0.010

1.162 (1.036-1.303)

Stage IV

-0.197

15.467

<.0001

0.821 (.744-.906)

Grade IV

3.756

677.843

<.000001

42.770 (32.236-56.745)

Grade III

3.697

2715.928

<.000001

40.339 (35.102-46.357)

Grade II

1.717

557.572

<.000001

5.569 (4.829-6.422)

Radiation None

0.095

18.680

<.00001

1.099 (1.053-1.148)

Black

> 40 years
Hispanic * >40
years of age
Asian Indian
* >40 years of age

Household
$5000-7999 (in
tens)
Histology (lobular
type)
Histology (Mixed
type)
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Table 4.4 continued
NH Black*Stage

0.144

4.307

0.038

1.155 (1.008-1.323)

-0.444

6.624

0.010

0.641 (.457-.900)

-0.127

6.851

0.009

0.881 (.801-.969)

-0.422

4.814

0.028

0.656 (.450-.956)

-0.381

4.202

0.04

0.683 (.474-.983)

0.827

4.917

0.027

2.286 (1.101-4.747)

1.511

4.053

0.044

4.531.041-19.724)

III
NH Black *
Grade III
NH Black *
Median
household
$5000-7999
Hispanic* Grade
II
Hispanic* Grade
III
Chinese * Stage
IV
Chinese * Median
household
$ 8000-12397
Note: * - Interaction effect
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TNBC women were significantly (p < .00001) more likely to be ductal carcinoma
compared to lobular or mixed subtype (OR = 0.23, 0.28 respectively). TNBC women
were at significantly higher odds (p < .0001) to be stage I compared to Stage IV (OR =
0.821, 95% C.I. = 0.74-0.91) and TNBC women were non-significantly (p = 0.53) more
likely to be stage II and less likely to be Stage III (p = 0.11). TNBC women were 5.57, 40,
and 42 times significantly (p < 0.0001) more likely to be Grade II, III, and IV
respectively when compared to Grade I. Compared to receiving radiation, TNBC women
were significantly (p < 0.0001) more likely to receive no radiation (OR = 1.1, 95% C.I. =
1.05-1.15).
Based on interaction effects, Hispanic women less than 40 years of age were at
significantly higher odds for TNBC (p = 0.017) and Asian Indian women less than 40
years of age were at significant higher odds for TNBC compared to NH White women of
the same age group (p = 0.049). NH Black and Hispanic women were significantly (p =
0.010, 0.040 respectively) at lesser odds for Grade III compared to Grade I TNBC tumors
compared to NH White women. NH Black are significantly (p = 0.038) at higher odds for
Stage III compared to Stage I TNBC tumors compared to NH White women. Hispanic
women were significantly 2.3 times more likely for Stage IV compared to Stage I TNBC
tumors compared to NH White women (p = 0.027). Among women who did not receive
radiation, NH Black women were significantly less (p = .038) likely than NH White to be
in TNBC group.
Similar interaction effects were observed between ethnicity and income level.
Chinese women with median household income $8,000-12,397 (in tens) are 4.5 times
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more significantly (p = 0.044) likely to be TNBC versus NH White women of same
median household income level. NH Black women with income <$5000 (in tens) are at
significant (p = 0.009) higher odds for TNBC versus NH White women of same median
household income level. Stage III NH Black women are significantly (p = 0.038) at
higher odds for TNBC and Stage IV Chinese women are significantly 2.3 times (p =
0.027) more likely for TNBC compared to Stage I NH women. Persons below poverty
percent and surgery are non-significant (p > 0.05) predictors and was not included in the
final adjusted model.
Discussion
The findings from this study are consistent with previous studies showing that NH
Black women have the highest frequency for TNBC (Parise & Caggiano, 2014; Parise &
Caggiano, 2013; Howlader et al., 2014; Iqbal, Ginsburg, Rochon, Sun, & Narod, 2015;
Tao et al., 2015; Swede et al., 2011; Morris et al., 2007; Lund et al., 2010) followed by
Asian Indian, Hispanic, and Korean women (Plasilova et al., 2016). Additionally, we
reported the following order: for TNBC frequency Korean, NH White, Chinese,
Vietnamese and Filipino women, whereas Plasilova et al. study published Chinese
women with higher TNBC frequency than White women. Consistent with other previous
findings (Parise & Caggiano, 2016), Filipino women were the least likely to have a
TNBC diagnosis. Although women from the Indian subcontinent (Asian Indian, Pakistani,
Bangladeshi, Nepalese, Sikkimese, and Sri Lankan) were reported to have the highest
frequency in several studies (Parise & Caggiano, 2014; Parise & Caggiano, 2016; Telli et
al., 2011) while this study found Asian Indian women to have highest frequency after NH
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Black women. Our study also identified that Hispanic women have a higher frequency
than NH White, but a major difference was reported by Boone et al. (2014). Our study
provided further evidence of the need to explore the TNBC burden on the individual
ethnicities, separately.
Consistent with previous research (Banegas et al., 2014), our study reported
higher percentages of TNBC women in low and medium SES based on percentage of
persons below poverty which is a county attribute when compared to Non-TNBC cases.
Future studies need to explore below poverty percentages as a measure for SES and
confirm findings from this study. In contrast to published literature, this study reported
significant associations of TNBC with insurance status and median household income
and reported significant differences between TNBC and non-TNBC groups for those two
variables. Only non-significant associations between TNBC and insurance status had
been previously reported in the literature (Llanos et al.; Telli et al.; Trivers et al. 2009;
Banegas et al.) and non-significant differences between TNBC and income level (Llanos
et al.,2015; Dolle et al., 2009).
Consistent with findings of previous studies, TNBC when compared to
Non-TNBC occur at a significantly younger age (Parise & Caggiano, 2017; Plasilova et
al., Matt, Mozayen, Gress, & Tirona; Orucevic et al.; Llanos et al.; Banegas et al.;
Ambrosone et al., 2014; Shinde et al., 2010; Chen et al., 2016; Bauer et al., 2007;
Santebennur et al., 2008; Kwan et al., 2009; Sineshaw et al., 2014; Brown et al., 2008;
Anders et al., 2011; Lund et al., 2008; Tawfik et al., 2010;). However, our study’s finding
varied in that the median age is 58 years for TNBC whereas Tawfik et al. (2010),
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reported 51 years as median age at diagnosis and Bauer et al. (2007) and Brown et al.
(2008) reported the median age at diagnosis as 54 years. It needs to be noted that unlike
our study, Bauer et al. and Brown et al. were single registry studies with cases diagnosed
between 1999 and 2003/04 while Tawfik et al. (2010) included only African American
and Caucasian women in their study. This could be a plausible reason for the difference
in the median age finding.
TNBC tumors when compared to Non-TNBC tumors present at later stages of
disease (Lin et al., 2012; Llanos et al.; Rummel et al.; Parise & Caggiano, 2017; Rizzo et
al., 2009; Brown et al., 2008; Bauer et al., 2007; Lund et al., 2010) and our study finding
contrasted Zaky et al. (2011) and Trivers et al. (2009) in they did not observe statistically
significant differences between TNBC and Non-TNBC groups. This could possibly be
due to age restriction of the study population to 20-54 years, small sample numbers
(n=476) (Trivers et al.) or sampling primarily based on a treatment, such as Breast
Conservation Therapy (Zaky et al.). Most published studies had reported TNBC tumor
sizes to be more than 2 centimeters in diameter at the time of presentation (Parise &
Caggiano, 2017; Plasilova et al; Llanos et al.; Banegas et al.; Santebennur et al., 2008;
Sineshaw et al., 2014; Lund et al., 2010; Kanaan et al., 2014). While our study supported
this finding, we found statistical significance (<0.001) when comparing TNBC and
Non-TNBC tumor sizes, 2cms versus 1.7 cms, respectively (Brown et al., 2008; Bauer et
al., 2007; Tawfik et al., 2010).
Consistent with published literature, TNBC tumors in this study presented with
advanced tumor grades (Llanos et al.; Rummel et al.; Parise & Caggiano, 2017; Brown et
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al.; Bauer et al.; Tawfik et al., Plasilova et al. 2016; Sineshaw et al.; Orucevic et al., 2015;
Morris et al., 2007; Lund et al., 2009; Lund et al., 2008; Banegas et al; Zaky et al., 2011;
Kanaan et al., 2014;). However, this study is the first to report statistically significant (p <
0.001) differences between TNBC and Non-TNBC tumors for lymph node involvement
as previous studies compared TNBC to Luminal type A cancer only (Plasilova et al.,
Llanos et al., 2015, Banegas et al., 2014). Consistent with previous findings (Plasilova et
al., 2016), TNBC is associated with metastasis (p < 0.001). However, our study was the
first to report metastatic findings for eight major races/ethnicities diagnosed in recent
years. For a comparison of the treatment variable between TNBC and Non-TNBC tumors,
major differences were noted for chemotherapy (36.6% versus 71% respectively) but
only slight differences noted for radiation (49.4% versus 45.7% respectively) and surgery,
although they all were statistically significant differences (p < 0.001). Chemotherapy data
needs to be interpreted with caution due to the low sensitivity (68%) of the information
provided by the SEER (Noone et al). Among TNBC cases, our study found 63.4% of
women to not receive chemotherapy, but as SEER cautioned we need to pay attention to
understand that the 63.4% is a collective grouping of those who did not receive
chemotherapy and those on whom chemotherapy information is not known. This caution
prevents researcher bias in interpreting the results.
Consistent with previous studies, NH Black women were found to have
significantly higher odds for TNBC compared to NH White women (Kwan et al., 2009; Lin
et al., 2012; Sineshaw et al., 2014). Our study reported a 70% increased probability for
Hispanics to develop TNBC compared to NH White women. Previous literature had
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reported 17% probability of TNBC compared to the HR+/HER2- subtype only. Filipino
and Vietnamese women had higher odds for TNBC, however they were non-significant
findings. Further research targeting these ethnicities is needed to confirm our findings.
Our study reported Asian Indian women less than 40 years of age to have higher
odds for TNBC compared to NH White women. A previous study had reported NH Black
women less than 40 years of age to be at increased risk for TNBC while our study did not
find this to be at a level of significance (Anders et al., 2011). Our study reported 15%
increased risk for NH Black women with Stage III cancer compared to NH White women
with Stage III breast cancer to be TNBC.
Also, previous studies that reported TNBC frequencies in Asian Indians always
grouped them with women from Pakistan, Sri Lanka, Bangladesh, Nepal and Sikkim
(Iqbal et al., 2015; Parise & Caggiano, 2014; C. Parise & Caggiano, 2016; Telli et al.,
2011) . Rao et al. (2011) and Plasilova et al. (2016) reported TNBC frequency for Asian
Indians, but the sample from the Rao et al. (2011) study included women in Stages 0-II
only. Plasilova et al. used a sample from a shorter time frame of two years compared to
our study that included women with stages I-IV over four years. Our study is the first to
show significant (p = 0.49) increased odds for TNBC among the Asian Indian women
alone who are less than 40 years of age without grouping them with other ethnicities. NH
Black women with stage III were reported to have a risk for death due to breast cancer
death (Tao et al., 2015) . These findings among NH Black and Asian Indian women
highlight the need for TNBC prevention through genetic counselling followed by testing
(Rummel, Varner, Shriver, & Ellsworth, 2013).
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Deleterious mutations in BRCA 1 had been reported among TNBC women
(Sharma et al., 2014; Lynce et al., 2015; Rummel et al., 2013; Sharma et al., 2014;
Gonzalez-Angulo, et al. 2011). TNBC status is a predictor for BRCA 1/2 mutation on
univariate analysis (Lynce et al.). Lynce et al. further reported that one in seven black
women who underwent genetic counseling had a positive result for BRCA 1/2 mutation.
Hence our findings urge healthcare providers to make referrals for genetic counselling
and testing for the high-risk ethnic women
Our study confirmed that TNBC women are at significantly (p = 0.001) higher
odds to be in households with lower income (less than $5,000, in tens) compared to
higher income levels (Sineshaw et al., 2014, Parise & Caggiano, 2014). NH Black
women with median household incomes less than $5,000 (in tens) are at significant (p =
.009) higher odds for TNBC compared to NH White women. Similarly, Chinese women
with Median household income between $8,000 and $12,397 (in tens) are significantly
4.5 times (p = 0.044) likely to be TNBC compared to women with income less than
$5,000 (in tens). Other studies had used median household income along with education
level, insurance status, and we do not have previous findings to compare with ( Parise &
Caggiano, 2017; Sineshaw et al., 2014). Compared to women with insurance, uninsured
women are more likely to be in TNBC group, findings similar to Sineshaw et al.
Our study reported consistent findings related to TNBC tumor histology (ductal
carcinoma) (Swede et al., 2011), tumor grade (higher grades) (Kanaan et al., 2014; Llanos
et al., 2015; Orucevic et al., 2015; Sineshaw et al., 2014; Telli et al., 2011). We reported
significantly 5, 40 and 42 times more likely to be Grades II, III, and IV respectively,
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compared to grade I (p < 0.0001) whereas previous studies had only reported 10 to 20 times
(Howlader et al., 2014; Llanos et al., 2015). NH Black women had significantly lesser odds
for grade III tumors while Hispanic women had significantly lesser odds for Grade II and
III compared to Grade I tumors (p = 0.10, 0.028, 0.04 respectively). Our results contrasted
Parise et al. (2017) and Iqbal et al., (2015) and Banegas et al. (2014) who found higher odds
for TNBC tumors to be higher grade for these ethnic women. Since NH Black and Hispanic
women were at increased odds for lower grade tumors these women may benefit from early
detection and plausible improved survival outcomes.
TNBC women were 10% less likely (p < 0.00001) to receive radiation compared to
those who received radiation. Our study reported NH Black women who did not receive
radiation were significantly (p = 0.038) less likely to be TNBC. This finding needs to be
confirmed by further research as a previously study reported no significance (Dawood et al.,
2009).
In contrast to previously reported findings, our study reported significant higher
odds (p < 0.0001) for TNBC tumors to be Stage I compared to Stage IV (Zaky et al., 2011).
NH Black women with Stage III and Chinese women with Stage IV breast cancers are 1.15
and 2.3 times significantly more likely to develop TNBC compared to NH White women (p
= 0. 038, 0.027 respectively). Our findings supported the report by Chen and Li (2015) on
African American women but contrasted their findings on Chinese women with stage IV
tumors who were significantly more likely to be TNBC compared to NH White women (p
= 0.027).
Limitations
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Firstly, the lack of detailed information on chemotherapy and hormone therapy on
all cases. The chemotherapy information given from SEER included unknown cases for
receiving chemotherapy along with those women who did not receive chemotherapy.
Currently SEER is undertaking efforts to provide more information on chemotherapy
details of patient. Secondly, clinical information on family history, BRCA gene testing
results and demographic information such as educational and nativity status are
unavailable in SEER data. Thirdly, we did not create a composite score for SES due to
non-availability of individual’s income and education level. Finally, for the model
prediction, the classification table gave 88.7% correct, but almost all cases were predicted
to be in the non-TNBC group.
Strengths of the study are that the proportion of foreign-born persons is higher
among SEER cases compared to general U. S. population and the study’s interest was to
examine the TNBC burden among Asian ethnicities. A large sample number, inclusion of
eight major race/ethnicities of women more than 18 years of age was a strength of this
study. This could also be the reason for our study to reach statistical significance of p <
0.001 between the TNBC and non-TNBC group whereas some studies did not. Another
strength of the study is the inclusion of Asian women subdivided into individual ethnic
groups in identifying associations with TNBC and model prediction.
In summary, significant differences exist between TNBC and non-TNBC groups
for clinical and demographic characteristics of tumors. Ethnic differences exist among
groups for clinical and demographic categories. For example, NH Black women are more
likely to present with TNBC compared to NH White and Asian Indian women who are less
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than 40 years of age, are significantly more likely to be in the TNBC group versus the
non-TNBC group. Further research is warranted to confirm our study findings and to
further explore the ethnic differences that exist between the groups. Clinically, these
high-risk women need to be identified and followed for early detection of TNBC tumors.
The literature cites a high frequency of TNBC tumors that had been self-detected compared
to Luminal type A tumors (Llanos et al.; Lin et al., 2012;). While not a variable available
for inclusion in this study, this approach could promote early detection in this high-risk
group. Community educational programs need to be initiated to reach ethnic women to
encourage self-assessment for early detection of these triple negative breast tumors.
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CHAPTER 5
CONCLUSIONS
This chapter summarizes the main findings, discussions, limitations, implications,
and recommendations of the dissertation. It presents and discusses the similarities and
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differences between the three manuscripts. An explanation of how the study contributed
to the extension of existing knowledge on the problem of TNBC in women of color and
the interventionist track of Healthcare Genetics is included. Knowledge gaps are
identified and an agenda is presented for future work.
Findings from this Research
Non-Hispanic/NH Black had the highest rate of 516.17 (per 100,000) followed by
NH White women at 287.92, Hispanic women at 212.91, and 190.60 for Asian Pacific
Islander women. Among NH Whites, women 70-74 years had the highest TNBC
incidence rate followed by 65-69-year-old (35.84 and 33.65 per 100,000 respectively).
Among NH Blacks, 60-64 years of age had the highest rate followed by 65-69 years of
age (62.43 and 59.41 per 100,000 respectively). For Hispanic women, those 65-69 years
of age had the highest rate followed by 70-74 years of age (24.81 and 22.54 per 100,000
respectively), Asian/Pacific Islander was the only group who had the highest age-specific
rate among women aged 80-84 years (22.084) followed by 65-69 years old women (20.73
per 100,000).
For phenotypic and treatment characteristics, differences among races/ethnicities
were noted. NH Black women with TNBC had the highest frequency for: Stages III and
IV (18.5% and 8% respectively); positive metastasis (8%); positive lymph node invasion
(42%); and not having a surgical treatment (10.2%). Asian Indian women were: the
youngest (median age at 47 years); had the highest frequency for grade III tumors
(84.7%); to receive chemotherapy (85.5%); receive radiation (51.9%); who underwent
surgery (95.4%); Korean women had the highest frequency (2.4%); for grade IV; and for
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receiving no radiation (56.3%). All groups were similar in being ductal carcinoma for
tumor histology.
Among TNBC cases, NH Black women had the highest frequency (21.25%)
followed by Asian Indian (12.96%), Hispanic (12.69%), Korean (12.1%), NH White
(10.3%), Chinese (9.38%), Vietnamese (9.1%), and Filipino women (8.44%). Compared
to non-TNBC women, TNBC women were observed to be youngest for median age at
diagnosis (58 years), and higher proportions to be uninsured, in low socio economic
status, with median household income between $1,915 to $5,999 (in tens), tumor stages II
and above, larger tumor sizes, tumor grades III and above, infiltrating ductal carcinoma,
positive for metastasis, and to receive chemotherapy for treatment. Future research is
needed to examine the relationship between low SES and TNBC phenotypic
characteristics among the eight race/ethnic groups.
Using a binary logistic regression model the results predicted Hispanic women
and Asian Indian women less than 40 years of age, NH Black Stage III women, NH
Black women with income less than $5000 (in tens), Hispanics with Grade I, women with
Stage I tumors; Chinese women with median household income $8000-12397 (in tens)
had higher odds to be TNBC. Among treatment variable categories, only radiation
(receiving none) was found to be a significant predictor (p < 0.001) for TNBC.
Limitations
The study had few limitations and they are related to sample information available
from SEER. Firstly, there was a lack of population count for the five Asian ethnicitiesChinese, Asian Indian, Filipina, Korean and Vietnamese preventing the calculation of the
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respective incidence rates which prevented us from identifying the TNBC burden among
those populations of women. Secondly, there was a lack of information on the nativity
status of the women (U.S. or foreign-born), completed education level (less than high
school, high school, college, graduate), chemotherapy, and hormone therapy information.
These data will add value to the clinical assessment of TNBC cases. SEER is currently
undertaking efforts to add that information to its records. Thirdly, lack of family history,
and results from genetic tests hindered the inclusion of significant variables in the
prediction model. Finally, the large sample size could be a limitation itself as statistical
tests reach significance due to the large numbers and presence of a true
association/relationship needs to be verified (Kaplan, Chambers, & Glasgow, 2014).
Discussion
The most recent epidemiological results available on TNBC were reported in this
study. Previously published studies reported on cases diagnosed in the years 2006-2009
(Clarke et al., 2012) and in 2010 (Howlader et al., 2014). Our study included women
diagnosed, from 2010-2013. Hence the age-adjusted incidence rate and age-specific
incidence rates are the most recent and not published prior to 2014. Although ranking
(highest to lowest) of races/ethnicities for age-specific rates is the same as previously
published studies (Kohler et al., 2015; Plasilova et al., 2016), there is a change in the peak
age for TNBC incidence among NH Black, NH White, Hispanic, and Asian / Pacific
Islander women.
The Asian Indian population is one of the fastest growing groups in the U.S.,
~70% increase from 2000 to 2010 (Hoeffel, Rastogi, Kim, & Shahid, 2012). Only since
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2010 has SEER recorded Asian Indian women as a separate ethnicity with previously
published studies including Pakistani, Bangladeshi, Nepalese, Sikkimese, or Sri Lankan
women grouped with Asian Indian women; Vietnamese women were also grouped with
neighboring countries as “South Asian” women in research studies (Parise & Caggaino,
2016). However, our study provided phenotypic and treatment information for TNBC that
was previously unavailable on Asian Indian and Vietnamese women as well as for six
other groups.
This dissertation study is the first to show evidence on TNBC specific frequency
among Asian ethnicities as previous studies published on Indian subcontinent women or
Asian Pacific Islander women (Parise & Caggiano, 2016; Parise & Caggiano, 2014;
Plasilova et al., 2016). Our study found (Chapter 4 results) Asian Indians ranked second
in TNBC frequency next to NH Black, followed by Hispanic, Korean, NH White,
Chinese, Vietnamese, and Filipina women. Asian Indian women less than 40 years were
at higher odds for TNBC, a new finding. Unlike previously reported results, our study
found Chinese women less frequently were diagnosed with TNBC compared to NH
White. Chinese women with a median Household income between $8,000-12,397, and
Chinese women with Stage IV tumors had higher odds for TNBC, again were new
findings. This contrasted with the results of Chen and Li’s (2015) study. Our report of a
significant association between TNBC and the median household income variable was
also in contrast to other previous studies (Llanos et al., 2015, Dolle et al.).
A significant association was found between insurance status and TNBC, unlike
previous studies (Llanos et al.; Telli et al., 2011; Trivers et al., 2009; Banegas et al.,
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2014). Also, previous studies reported median age for TNBC as 51 years (Tawfik et al.),
54 years (Bauer et al., 2008; Brown et al., 2008), whereas our study reported a median
age of 58 years. The higher median age reflects the higher age-specific incidence rates in
the age-groups 60-64, 65-69 years, and 70-74 years.
Consistent with previous literature, NH Black women with Stage III disease were
at higher odds for it to be TNBC (Chen & Li, 2015). NH Black with an income less than
$5,000 as a TNBC predictor is a new finding in our study. NH Black women with a
Grade III tumor or Hispanic women with Grades II and III tumors were found to be
significant predictors for TNBC, but these variables were less likely to predict TNBC
compared to non-TNBC tumors.
In contrast to previously published literature (Zaky et al., 2011; Dawood et al.,
2009; Iqbal et al., 2015), our study reported significant differences among the eight
race/ethnic groups for the demographic and phenotypic characteristics. Also, Stage I but
not Stage II, III or IV as published in the literature (Telli et al., 2011), was a significant
predictor for women to be in the TNBC group. Telli et al. sampled women from the
California Cancer Registry (diagnosed cases 2002-2007) to predict odds for TNBC
compared to HR+/HER2- women and found Stages II and above to be highly likely to be
TNBC, but was a non-significant finding.
Similarities and differences between the three manuscripts
The similarities between chapter three and chapter four manuscripts are in terms
of the sample and the primary problem of study. Chapter three and four provided
information on eight groups of women (Non-Hispanic White, Non-Hispanic Black,
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Hispanic, Filipina, Chinese, Asian Indian, Korean and Vietnamese) with TNBC. The two
manuscripts discuss information on cases diagnosed from 2010 to 2013. All information
is from a single source which is the SEER data.
There are many differences identified between the three manuscripts. Chapter
two synthesized the information retrieved from literature published from 2007 (January)
to 2017 (February). Chapter three reported age-adjusted and age-specific incidence data
on TNBC for the eight groups, adjusted to Standard United States 2000 population. It
also provided information on the phenotypic, demographic, and treatment characteristics
of TNBC cases. Chapter four reported findings on TNBC phenotypic, demographic, and
treatment characteristics compared to Non-TNBC cases, and reported odds for TNBC
based on a prediction model. Chapter four included Non-TNBC cases in the sample,
whereas manuscript three included TNBC cases only. These are the major similarities and
differences noted between the three manuscripts.
Coherent Body of Work
Chapter two discussed the literature search that was done on published journal
articles on the selected problem. It provided information that was already available about
the problem, the significance of the problem, and available information on
races/ethnicities. Knowledge gaps were identified and the research proposal was
developed. Manuscript three discussed the findings from the study that answered two
research questions- incidence of TNBC, both age-adjusted and age-specific, as well as the
clinical presentation and pathologic features of TNBC. It was focused on the eight
race/ethnic groups of interest. Chapter four manuscript discussed the findings about
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TNBC, but in comparison with Non-TNBC cases. All cases were compared on the
different variables, and were used to develop a prediction model. The first model was an
unadjusted model that used the race/ethnic information only, but the successive models
included many other variables and the interaction effects. The final model included
significant predictor variables and the interaction effects. From the model, the higher and
lesser odds for developing TNBC was obtained.
Contribution to the Knowledge regarding the problem and the specialty area of
HCG
Our study’s sample is the first to include TNBC and Non-TNBC cases from all
18 SEER registries for the years 2010 to 2013, ages 18 years and above, and all stages of
TNBC. Our study contributed knowledge regarding TNBC incidence rates on major races
(NH White, NH Black, and Hispanic) and Asian sub-ethnicities (Chinese, Asian Indian,
Filipina, Vietnamese, and Korean) in the U. S.
Our study is the first to report statistically significant differences between ethnic
groups for TNBC stage, tumor grade, tumor histology, tumor size, lymph node
involvement, metastasis, and treatment. In contrast to published literature, our study
reported significant association of TNBC with insurance status and median household
income. In contrast to previously reported findings, our study reported significantly
higher odds (p < 0.0001) for TNBC tumors to be Stage I compared to Stage IV.
Consistent with previous findings (Plasilova et al.), TNBC is associated with metastasis (p
< 0.001). However, our study was the first to report findings for eight major
races/ethnicities diagnosed in the recent years for metastasis
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TNBC phenotypic differences among ethnicities such as Hispanic and Asian
sub-groups were not available in the literature when compared to NH White and NH
Black populations. We added more knowledge to TNBC among Asian subgroups:
Chinese women with stage IV tumors significantly more likely to be TNBC compared to
NH White women (p = 0.027). Our study also found Asian Indian women to have highest
frequency next to NH Black women and significant (p = 0.49) increased odds for TNBC
compared to NH White women. Our study reported a 70% increased probability for
Hispanics for TNBC compared to NH White women and previous literature had reported
17% probability compared to HR+/HER2.
The study contributed to the “Interventionist” specialty track of HCG by
providing information on groups of population on an issue that has genetic risk factor as
per literature. The study contributed by laying the foundation for addressing the problem
“TNBC disparity among ethnicities.” The study highlighted the current burden of TNBC
and statistically proved that there are significant differences between ethnicities for
phenotypic characteristics, demographics, and treatment options. These differences
impact the outcome of the disease. A HCG interventionist can use this information to
counsel women who may fall into the high-risk category, based on the predictors from
our adjusted prediction model. Applying the Health Belief Model to our problem of
interest, a person can perceive their susceptibility only when cancer statistics are
available specific to them. Now that the cancer statistics are available from our study,
women from Asian, Hispanic and Black races/ethnicities can be provided with this
information and alerted for their high-risk status. As per the Health Belief Model, when
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an individual perceives the seriousness of the disease, self-efficacy plays a role. The
individual can adopt a healthy behavior, which could be preventive or early detection.
Using the study findings along with other risk assessment scales that are available, the
women can be presented with information on genetic testing available for TNBC. A HCG
interventionist can also be involved by using the study findings as an educational material
to encourage a person towards an early detection behavior such as consistent high-risk
screening practices (cues to action).
Knowledge Gaps
Firstly, we do not have information on incidence rate for the Asian
sub-ethnicities from the recent years. The study provided TNBC frequency data, but not
the adjusted incidence rate as SEER does not have the population count for the Asian
sub-ethnicities. Secondly, although a countrywide database, SEER does not provide
information on variables such as education, family history, genetic tests, country of origin,
metabolic syndrome, reproductive factors (breast feeding, hormone therapy information,
parity, and others) and lifestyle factors such as smoking, alcohol consumption, caffeine
intake. Thirdly, the SEER variables that were county attributes from the American
Community Survey may only reflect the individual’s household income, poverty percent
but not provide accuracy. The education level and annual income of individual versus a
county could best contribute to the TNBC prediction model by providing more accuracy.
Recommendations and Implications for Future Research
Clinical Recommendations
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Literature suggested that healthcare providers may not have the necessary
understanding to recommend genetic counseling and genetic testing to underserved and
minority women (Ricks-Santi & McDonald, 2016). A healthcare provider’s referral and a
woman’s race/ethnicity were significant predictors for genetic testing (Ricks-Santi and
McDonald; Cragun et al., 2015; Thompson et al., 2012) Based on our study, compared to
NH White, NH Black and Hispanics were at increased risk for TNBC. Four studies done
among TNBC cases reported prevalence on BRCA mutation, ranging from 9% to 21.4%
(Gonzalez-Angulo et al., 2011; Lynce et al., 2015; Rummel et al., 2013; Sharma et al.,
2014) Using the findings of the study, along with evidence that BRCA 1 mutations are
prevalent among TNBC cases, healthcare providers should clinically identify high-risk
women for TNBC and recommend genetic testing and genetic counselling.
The literature stated that a majority (60%) of TNBC tumors are self-detected (Lin et
al., 2012; Llanos et al., 2015), almost one-third of tumors are detected via mammogram,
and a majority present with symptoms when compared with Luminal A cancers (Lin et al.,
2012). Hence clinicians should clinically screen for high-risk women based on
race/ethnicity, age at diagnosis, insurance status, and median income level. Although
insurance status and median income level has been reported, in the literature, to have no
significant association, we include it as our study found significant association. These
women should be advised for regular screening based on the U.S. Preventive Services
Task Force Recommendation Statement (Siu, 2016).
Women in obstetrics and Gynecology, oncology settings had higher rates for
physician recommendation and genetic counseling (Armstrong et al., 2015; Thompson et
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al., 2012), whereas women with less education, Black women with no insurance, or
foreign-born Black women were significantly less likely to receive the recommendations
(Thompson et al.). The study’s results suggest that clinicians should re-evaluate their
approach in reaching the Asian sub-ethnicities, NH Black, and Hispanic women.
Educational Recommendations
Physicians should be educated on utilization of genetic tools and make referrals for
personalized cancer treatment (Ricks-Santi & McDonald). Clinical services in hospitals
and other institutions should develop educational materials in the language of the ethnic
minorities to provide them information on how TNBC can be prevented, detected early,
and treated. Community educational programs should be conducted to increase the
awareness about TNBC, its incidence, prophylactic treatment across all ages of women.
Educational programs need to be developed to equip healthcare providers with
information on incidence, clinic-pathologic characteristics of TNBC, and genetic
susceptibility. MacNew et al. (2010) recommended educational efforts on BRCA testing
and its benefits to target less educated and minority groups.
Future Research
The recommendations for future research include to:
1. calculate incidence rate using a state registry or a national database that has
population count for Asian sub-ethnicities to obtain individual rates on Asian
sub-groups
2. further explore the role of TNBC risk factors including, but not limited to, genetic
mutations, family history, nativity status, age, income, education, insurance,
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reproductive factors (menarche, menopause, parity, breast feeding, oral
contraceptive pill usage, hormone therapy), metabolic syndrome, obesity, lifestyle
(exercise, smoking, alcohol) and others at a large-scale level.
3. develop a TNBC risk assessment scale using the predictors from the model and
other significant variables to identify high-risk women of color.
4. explore validity of ‘persons below poverty percent’ as a measure for SES and
confirm our findings.
5. assess for differences between TNBC cases and controls for TNBC phenotypic
and demographic characteristics, for usage of services such as clinical breast
examination, mammogram screening, Breast Ultrasound, Breast MRI along with
the study variables among the eight races/ethnicities.
6. assess stage I as a significant indicator for high-risk status in a smaller sample size
study
7. develop qualitative study to assess an individual’s perception of risk before and
after presenting the TNBC incidence and frequency information and to understand
the process of making decisions towards genetic testing and genetic counseling.

Summary
This chapter summarized the main findings, discussions, limitations, implications,
and recommendations of the dissertation. Similarities and differences between the three
manuscripts were presented and discussed. An explanation of contributions to existing
knowledge on the problem of TNBC in women of color and the interventionist track of
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Healthcare Genetics was included. Knowledge gaps were identified and an agenda was
presented for future work.

References
Armstrong, J., Toscano, M., Kotchko, N., Friedman, S., Schwartz, M. D., Virgo, K. S., . . .
Bauer, J. E. (2015). Utilization and outcomes of BRCA genetic testing and counseling

176

in a national commercially insured population: The ABOUT study. JAMA Oncology,
1(9), 1251-1260.
Banegas, M. P., Tao, L., Altekruse, S., Anderson, W. F., John, E. M., Clarke, C. A., &
Gomez, S. L. (2014). Heterogeneity of breast cancer subtypes and survival among
Hispanic women with invasive breast cancer in California. Breast Cancer Research
and Treatment, 144(3), 625-634.
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive
analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and
HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype.
Cancer, 109(9), 1721-1728.
Brown, M., Tsodikov, A., Bauer, K. R., Parise, C. A., & Caggiano, V. (2008). The role of
human epidermal growth factor receptor 2 in the survival of women with estrogen and
progesterone receptor‐negative, invasive breast cancer: The California cancer registry,
1999–2004. Cancer, 112(4), 737-747.
Chen, L., & Li, C. I. (2015). Racial disparities in breast cancer diagnosis and treatment by
hormone receptor and HER2 status. Cancer Epidemiology, Biomarkers & Prevention:
A Publication of the American Association for Cancer Research, Cosponsored by the
American Society of Preventive Oncology, 24(11), 1666-1672. doi:
10.1158/1055-9965.EPI-15-0293 [doi]
Clarke, C. A., Keegan, T. H., Yang, J., Press, D. J., Kurian, A. W., Patel, A. H., & Lacey, J.
V.,Jr. (2012). Age-specific incidence of breast cancer subtypes: Understanding the

177

Black-white crossover. Journal of the National Cancer Institute, 104(14), 1094-1101.
doi:10.1093/jnci/djs264 [doi]
Cragun, D., Bonner, D., Kim, J., Akbari, M., Narod, S., Gomez-Fuego, A., . . . Pal, T.
(2015). Factors associated with genetic counseling and BRCA testing in a
population-based sample of young Black women with breast cancer. Breast Cancer
Research and Treatment, 151(1), 169-176.
Dawood, S., Broglio, K., Kau, S. W., Green, M. C., Giordano, S. H., Meric-Bernstam,
F., . . . Hennessy, B. T. J. (2009). Triple receptor–negative breast cancer: The effect of
race on response to primary systemic treatment and survival outcomes. Journal of
Clinical Oncology, 27(2), 220. doi:10.1200/JCO.2008.17.9952
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone,
K. E. (2009). Risk factors for triple-negative breast cancer in women under the age of
45 years. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the
American Association for Cancer Research, Cosponsored by the American Society of
Preventive Oncology, 18(4), 1157-1166. doi: 10.1158/1055-9965.EPI-08-1005 [doi]
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., . . .
Meric-Bernstam, F. (2011). Incidence and outcome of BRCA mutations in unselected
patients with triple receptor-negative breast cancer. Clinical Cancer Research: An
Official Journal of the American Association for Cancer Research, 17(5), 1082-1089.
doi: 10.1158/1078-0432.CCR-10-2560 [doi]
Hoeffel, E. M., Rastogi, S., Kim, M. O., & Shahid, H. (2012). The Asian population: 2010.
the census briefs. (No. C2010BR-11).U.S. Department of Commerce

178

Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A., & Cronin,
K. A. (2014). US incidence of breast cancer subtypes defined by joint hormone
receptor and HER2 status. Journal of the National Cancer Institute, 106(5),
10.1093/jnci/dju055. doi:10.1093/jnci/dju055 [doi]
Iqbal, J., Ginsburg, O., Rochon, P. A., Sun, P., & Narod, S. A. (2015). Differences in breast
cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the
united states. JAMA, 313(2), 165-173.
Kaplan, R.M., Chambers, D.A. & Glasgow, R.E. (2014). Big Data and Large Sample Size:
A Cautionary Note on the Potential for Bias. Commentary. Clinical and Translational
Science. 7 (4).342-346
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., . . .
Penberthy, L. (2015). Annual report to the nation on the status of cancer, 1975-2011,
featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state.
Journal of the National Cancer Institute, 107(6), djv048. doi:10.1093/jnci/djv048
[doi]
Llanos, A. A., Chandwani, S., Bandera, E. V., Hirshfield, K. M., Lin, Y., Ambrosone, C. B.,
& Demissie, K. (2015). Associations between sociodemographic and
clinicopathological factors and breast cancer subtypes in a population-based study.
Cancer Causes & Control, 26(12), 1737-1750.
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., . . .
Weeks, J. C. (2012). Clinicopathologic features, patterns of recurrence, and survival

179

among women with triple‐negative breast cancer in the national comprehensive
cancer network. Cancer, 118(22), 5463-5472.
Lynce, F., Smith, K. L., Stein, J., DeMarco, T., Wang, Y., Wang, H., . . . Isaacs, C. (2015).
Deleterious BRCA1/2 mutations in an urban population of Black women. Breast
Cancer Research and Treatment, 153(1), 201-209.
MacNew, H., Rudolph, R., Brower, S., Beck, A., & Meister, E. (2010). Assessing the
knowledge and attitudes regarding genetic testing for breast cancer risk in our region
of southeastern georgia. The Breast Journal, 16(2), 189-192.
Parise, C., & Caggiano, V. (2014). Disparities in the risk of the ER/PR/HER2 breast cancer
subtypes among Asian Americans in California. Cancer Epidemiology, 38(5),
556-562.
Parise, C., & Caggiano, V. (2016). Breast cancer mortality among Asian-American women
in California: Variation according to ethnicity and tumor subtype. Journal of Breast
Cancer, 19(2), 112-121.
Ricks‐Santi, L. J., & McDonald, J. T. (2016). Low utility of oncotype DX® in the clinic.
Cancer Medicine, 6(3), 501-507. doi: 10.1002/cam4.837
Rummel, S., Varner, E., Shriver, C. D., & Ellsworth, R. E. (2013). Evaluation of BRCA1
mutations in an unselected patient population with triple-negative breast cancer.
Breast Cancer Research and Treatment, 137(1), 119-125.
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., . . .
Mammen, J. M. (2014). Germline BRCA mutation evaluation in a prospective

180

triple-negative breast cancer registry: Implications for hereditary breast and/or ovarian
cancer syndrome testing. Breast Cancer Research and Treatment, 145(3), 707-714.
Siu, A. L. (2016). U. S. Preventive Services Task Force. Screening for breast cancer: U. S.
Preventive Services Task Force recommendation statement. Annals of Internal
Medicine 164 (4): 279-296
Tawfik, O., Davis, K., Kimler, B. F., Davis, M. K., Hull, S., Fan, F., . . . Thomas, P. (2010).
Clinicopathological characteristics of triple-negative invasive mammary carcinomas
in African-American versus caucasian women. Annals of Clinical and Laboratory
Science, 40(4), 315-323. doi:40/4/315 [pii]
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H., McClure, L. A., Lichtensztajn,
D., . . . Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: A study from
the california cancer registry. Breast Cancer Research and Treatment, 127(2),
471-478.
Thompson, H. S., Sussner, K., Schwartz, M. D., Edwards, T., Forman, A., Jandorf, L., . . .
Valdimarsdottir, H. B. (2012). Receipt of genetic counseling recommendations among
Black women at high risk for BRCA mutations. Genetic Testing and Molecular
Biomarkers, 16(11), 1257-1262.
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J.
W. (2009). The epidemiology of triple-negative breast cancer, including race. Cancer
Causes & Control, 20(7), 1071-1082.

181

Zaky, S. S., Lund, M., May, K. A., Godette, K. D., Beitler, J. J., Holmes, L. R., . . . Landry,
J. C. (2011). The negative effect of triple-negative breast cancer on outcome after
breast-conserving therapy. Annals of Surgical Oncology, 18(10), 2858-2865.

182

APPENDICES

183

Appendix A
AJCC Staging for Breast Cancer

184

185

Appendix B
SEER Data-Use Agreement

186

Appendix C
IRB Extension Approval

187

Appendix D
Characteristics of 16 patients with clinically important BRCA1 mutations

Table retrieved from Rummel et al., 2013. Copyright permission obtained.

188

Appendix E
Copyright Permission for Appendix D

189

Appendix F
Receipt for manuscript submission

190

